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ABSTRACT

The purpose of this research was to design a blood glucose sensing system based on the
induced shift in the resonant frequency of an antenna patch operating in the ISM band (5.725 –
5.875 GHz). The underlying concept is the fact that when a person has variations in their blood
glucose levels, the permittivity of their blood varies accordingly. This research analyzed the
feasibility of using an antenna patch as a blood glucose sensing device in three configurations:
1) as an implantable active sensor, 2) as an implantable passive antenna sensor, and 3) as a
non-invasive sensor. In the first arrangement, the antenna is to be implanted inside the body as
an active antenna, requiring that its power supply and internal circuitry to be implanted. In the
second arrangement, the antenna is also implanted, but would not require a power supply or
internal circuity since it would be passive. For the third arrangement, the non-invasive sensing
approach, the antenna is placed facing the upper arm while mounted outside the body. In order
to evaluate the best approach all the three approaches were simulated using the electromagnetic
field tool simulator ANSYS EM15.0 HFSSTM, along with a human tissue model. The tissue model
included physiological and electrical characteristics of the human abdomen for simulating the
active and passive approaches, and the upper arm for the non-invasive approach.

The

electromagnetic boundaries were set with perfectly matched layers to eliminate any reflections
which would cause a non-physical resonance in the results. Simulation of the active sensing
configuration resulted in a resonant frequency shift from 5.76 to 5.78GHz (i.e., a 20 MHz shift) for
a simulated blood permittivity variation of 62.0 to 63.6. This corresponds, theoretically, to an
approximate glucose shift of 500 mg/dL. The passive configuration simulations did not yield
conclusive variations in resonant frequency and this approach was abandoned early on in this
research. Thirdly, the non-invasive approach resulted in a simulated shift of resonant frequency
ix

from 5.797 to 5.807 (i.e., a 10MHz shift) for simulated blood permittivity variation of 51.397 to
52.642 (an approximate variation of 2000 mg/dL in glucose). In the literature planar, continuous
blood-rich layers are used to simulate RF sensing of glucose, which is not applicable when
measuring glucose in actual human veins, which are tubular in geometry and of finite extent.
Therefore the model employed assumed a 1.8 mm diameter blood vessel, buried under a fatty
layer that was capped with skin. The above results, both simulated and verified experimentally,
used this more realistic model which is further proof that a practical non-invasive blood glucose
measurement system should be possible.
The non-invasive approach was tested experimentally by using oil in gel phantoms to
mimic the electrical properties of skin, fat, blood and muscle. A fat phantom was placed over a
muscle phantom, with a strip of blood phantom within and a skin phantom was placed on top.
The blood phantom had a 2000mg/dL variation of D-glucose in the phantom mixture which
decreased the relative permittivity from 52.635 to 51.482 and resulted in a shift of resonant
frequency from 5.855 to 5.842 (i.e., a 13MHz shift). This is consistent with the non-invasive
simulated results thus validating our model of the non-invasive sensing approach. While this
variation in blood glucose is non-physical (typical human glucose range can range in the extremes
from 30 to 400 mg/dL, where healthy glucose levels vary from 70mg/dL to 180mg/dL) it was
necessary to provide a high confidence fit between the simulated and experimental data. This is
because the level of precision with which the physical phantoms could be fabricated with was
insufficient to match the highly precise simulated data.
Analysis on the effect of lateral displacement of the antenna from the blood vessel, its
elevation above the skin and variations caused by different skin thickness, and blood vessel depth
were evaluated. A calibration technique to correct physical misalignment by the user is proposed
in which two additional antennas, located diagonally with respect to the sensing antenna, serve
as reference point for placement over the upper arm in line of sight with the blood vessel.

x

Once the non-invasive sensor approach was shown to be viable for continuous glucose
monitoring, a sensor platform was designed whereby an RF generator was used to drive the
antenna with a frequency sweep between 5.725 to 5.875GHz. A fraction of its output power was
coupled to both the antenna and the system analysis circuitry through a directional coupler. The
transmitted and received power were then processed with demodulating logarithmic amplifiers
which convert the RF signal to a corresponding voltage for downstream processing. Both inputs
were then fed into a microcontroller and the measured shift in resonant frequency, f O, converted
to glucose concentration which was displayed on glucose meter display.

xi

CHAPTER 1: INTRODUCTION

1.1 Overview of Glucose Monitoring
1.1.1 Diabetes and Self-Monitoring of Glucose Levels
The American Diabetes Association estimates that nearly 10% of the US population has
diabetes and that, by 2050, 1 in 3 Americans will have diabetes. Diabetes Mellitus is a metabolic
disease in which the body is unable to produce or properly use insulin, leading to elevated glucose
levels in the blood, known as hyperglycemia. A person with frequent or extended episodes of
hyperglycemia can suffer from complications in the nervous system, blood vessels and other
organs, as well heart disease, kidney disease, strokes, vision loss, and amputation [1] [2] [3].
Therefore, maintaining a healthy glucose level is essential in a person’s life.
Clinical studies have proven that self-monitoring of glucose levels helps treatment
decisions in insulin and non-insulin use patients with diabetes [1]. The Central and Eastern
Europe Diabetes Technologies and Therapeutics organization stated that self-monitoring glucose
is an “essential tool that should be accessible to all patients with diabetes” providing a report of
numerous benefits and recommendations [4]. Simply stated self-monitoring of glucose improves
health by allowing the patient to be able to take proper decisions based on their glucose levels [1]
[3]. Therefore, effective and feasible methods to measure blood glucose are essential.

1.1.2 Self-Monitoring Glucose Methods
A person can monitor their glucose levels via the conventional self-monitoring blood
glucose (SMBG) method by taking finger prick blood samples, or through continuous monitoring
glucose (CMG) means. For SMBG, the patient withdraws a drop of capillary blood sample from
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the fingertip to measure the blood glucose levels at that instant in time. [5] Since, in some cases,
patients are recommended to check their blood glucose at least 8 to 10 times a day, the repeated
procedure of finger pricking can be painful [6] and cause calluses over time thus increasing the
pain [7]. Additionally, since the results show instantaneous blood glucose levels, patients with
extreme conditions could suffer episodes of dangerous levels of glucose at instances that the
blood glucose is not being monitored [6].
On the other hand, CMG consists of a device that detects the patient’s glucose levels
continuously in real time, overcoming the problem of continuity. Unfortunately all currently FDA
approved CMG methods are short term, as the disposable needle-type is an amperometric
enzyme electrode that is inserted in the body and lasts only up to 14 days [8]. In addition to the
pain and hassle associated to the approximate weekly installation of the needle sensor, some
CMG require calibration four times a day with the finger sticking blood sample technique [3] [4]
since the measurement is not done directly on the blood glucose, but rather measures the glucose
of the interstitial fluid (ISF). Newer versions of CMG no longer require the calibration, but the
device itself and the cost of the disposable needle can make the these CGM systems marketed
by Medtronic, DexCom STS and Abbott FreeStyle Navigator result in elevated costs.

1.1.3 Developing Alternatives for Self- Monitoring Blood Glucose
Several alternatives for self-monitoring blood glucose (SMBG) have been researched over
the last years, striving to overcome the pain and hassle of 7 to 14 day sensor reinsertion and in
some CGM, calibrations with finger pricking techniques. Unfortunately, these new alternatives are
faced with numerous limitations and accuracy problems thus pointing to the critical need for a
more accurate, user-friendly CGM system to improve patience quality of life.
One approach is non-invasive technology, but no non-invasive technology has
successfully functioned in the market [9]. By way of example, the Glucowatch that came out in
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the market was discontinued after 2007 due to showing poor results and a serious defect of
burning patient skin [9] [10]., Other products, such as the Glucoband, Conga Medical Glucometer,
or C8MediSensors, have disappeared from the market [9] [11]. Several others are still under
development such as Biosensors [12], I-Sugar X Meditech [13], Easy Check [14], and EyeSense
[15], or not yet FDA approved, such as the GlucoTrack [16] and SCOUT [17]. Table 1 summarizes
a list of devices/companies for continuous glucose sensing technology with their status as of
October 2017, which does not include the discontinued devices Glucowatch, Diasensor and
Pendra [18], or products that have disappeared from the market. Last accessed October 2017.
Table 1: Summary of non-invasive devices/company’s status.
Device/
Company*
Biosensors

I-Sugar X
Meditech
EyeSense

Technology

Status

Source

SEMP technique
(Bioimpedance
spectroscopy)
Fluorescent technology

Under development
[12]

http://www.biosensors-tech.com/

Under development
[13]
Under development.
Launch postponed to
2015 [15]
Approved 2013 in
Europe. Not yet
approved by FDA
[16]
Not concluded. [19]

http://www.freedom-meditech.com/

Not concluded. [20]
Not concluded [17]

http://www.orsense.com/Glucose
http://www.veralight.com/products.
html

Fluorescent technology

GlucoTrack

Thermal, Ultrasound
and Electromagnetic
Technologies

Glove
Instruments
OrSense Ltd.
SCOUT DS,
Veralight Inc.

NIR Spectrosocopy
Occlusion technology
Fluorescent
spectroscopy

http://en.eyesense.com/

http://www.integrity-app.com/

http://groveinstruments.com/

Most non-invasive glucose monitoring systems face the challenge of being susceptible to
external interference from other factors such as body temperature, perspiration, skin moisture,
changes in skin thickness and body movement [13].

For instance, infrared spectroscopy,

including near infrared (NIR) spectroscopy and far infrared (FIR) spectroscopy, depend on optical
transmission and reflection measurements, which are subject to interference from external factors
that affect the reflection measurement. For this reason, NIR requires frequent recalibration. In
FIR, the emitted energy that is absorbed by glucose and measured is so small that this method
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has not yet been proven to be accurate enough for this application [7, 10]. In other methods, such
as Raman Spectroscopy, the measurement of light scattering that is caused by generated
oscillations such as laser oscillation in the ocular fluid is subject to interference from other
molecules [10, 18]. In thermal spectroscopy, the IR radiation that is emitted from the body is also
affected by other factors external to glucose concentration [10].

Another example is the

technology based on measuring the ISF fluid that is secreted from the skin to measure the glucose
levels which presents a time lag deficiency [21]. Overall, non-invasive technologies lack accuracy
due to being susceptible to external factors such as transpiration, temperature, positioning,
among other variables, or display time lags of up to 20 minutes, making the technology not yet
reliable [18]. This has led to discontinued devices such as the Glucowatch, Diasensor and Pendra
[18, 12] or have postponed the estimated launching date as is the case for the Eyesense.
Another approach towards self-glucose monitoring is a fully implantable glucose
monitoring system.

These medical devices face other types of challenges such as in-vivo

inflammatory reaction and foreign body reaction, posing risk for the patients and hence the need
for biocompatibility tests on any implantable device [22]. No current biosensor can operate for
longer than a few days in-vivo [23]. In a reaction to foreign materials, the body forms an
encapsulation around the object that is generally 100 microns thick, which not only acts as a
diffusion barrier, but is also electrically insulating. Therefore, long-term implantations are subject
to gradual loss of sensor functionality and stability due to fibrosis encapsulation and tissue
changes in proximity of the sensor [22, 24, 23].

Therefore, implantable devices, including

antennas, are coated with biocompatible materials, but in the aspect of communicating externally
from the body, this adds to the effects of sensor encapsulation [25].
In addition to the issue of biocompatibility, the life cycle of the implanted device is relevant
to factors such as the sensing mechanism inside the body and the energy required to function
properly. For instance, the developing device by GlySens is in trial stage and is expecting to start
taking preorders late 2018. The life cycle expectancy of this device is only one year after
4

implantation [26]. During the wide gap of research pertaining implantable devices, no
development has been proposed to function longer than 18 months due to one or more of the
previously mentioned challenges faced by implantable devices for a truly “long-term” implantable
solution.

1.2 Problem Statement
Statistical studies have proven the link between blood glucose levels and the incidence of
diabetes-related complications [3]. Ideally, patients with frequent or prolonged elevated glucose
levels should monitor their glucose levels continuously to be able to avoid the related
complications and improve their health. Although having a CGM system allows people with
diabetes to have better control of their health and life decisions, only 10% of the people with Type
I diabetes type use it, due to factors such as lack of education, and cost [5].
Other factors include fear of inserting the needle-like electrodes into their bodies, the
hassle of repeating this process once the disposable needle-like electrode reaches its life cycle
of 7 to 14 days, [6]. Other alternatives, such as implantable devices, have challenges such as
biocompatibility, an accurate and repeatable sensing mechanism, communication with the
exterior and the life time of electrical energy required for operation inside the body. For this
reason, developments such as long-term CGM by GlySens, while a significant step forward, will
only be effective up to 18 months after implantation.
Non-invasive alternative solutions could avoid the need for an implant as well as finger
pricking and insertion of disposable needle-like electrodes. Additionally, it could reduce the cost
of a surgery or the cost of disposable needles. For this reason, global research has been
concentrating on the search for an alternative blood glucose monitoring system, but to the best of
our knowledge, no non-invasive glucose monitoring system has been FDA approved for use and
while research in several institutions is on-going.
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1.3 Research Objective
The objective of this research is to analyze the viability of a blood glucose sensing system
based on the measurement of the shift of the resonant frequency of an antenna patch operating
in the 5.8GHz ISM band (5.725 – 5.875 GHz). The ISM band is approved by the FCC for medical
application and is therefore an ideal portion of the frequency spectrum to utilize for this application.
This research analyses blood glucose sensing via an implantable active sensor, an implantable
passive antenna sensor, and a non-invasive sensor by simulating the anticipated performance in
ANSYS EM15.0 HFSSTM, an electromagnetic field simulator ideally suited for this application.
Experimental tests for the most promising sensing method are conducted using oil-in-gel human
tissue phantoms which was found in the literature to be the most practical way to simulate blood
glucose variations in human blood.

1.4 Research Background
In a study conducted at the University of Alabama Birmingham Children’s Hospital, an
antenna operating between 500 MHz and 20 GHz showed a correlation between blood glucose
concentration and the dielectric constant and electrical conductivity of the blood [27]. This was
modelled using a single pole Cole-Cole equation. Different blood samples were collected and
manipulated in-vitro to analyze the blood glucose dependency. Based on this study, it was clear
that implantable and non-invasive systems need to undergo further research considering the
effect of other human tissues such as skin, fat and muscle.
An in-vitro demonstration of a biocompatible SiC antenna designed at 10 GHz, proposed
to be implanted inside the body in the fatty tissue near a blood vessel, was reported by Dr. Afroz
of our research group at USF. The system was simulated using synthetic and pig blood, and a
shift of 40 MHz and 26 MHz, respectively, was observed during in-vitro trials for a blood glucose
variation between 120 to 530 mg/dL [23] [28]. However, the operating frequency used in these
experiments (X-band) is not suitable for medical purposes, and the in-vitro setup did not mimic
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realistic human tissue surrounding the antenna under test; a planar blood layer, not blood vessels,
were used which are limited in their applicability to the real-life application.
In another study, a non-invasive blood glucose monitoring system was proposed using
two patch antennas radiating across a human tissue and blood setup, and operating at a
frequency of 60 GHz. The insertion loss, S21, was found to vary according to the glucose
concentration in water solution tests [29], demonstrating further evidence of the potential of
realizing a non-invasive glucose sensor. The current research differs by investigating the return
loss, S11, of the antenna sensor patch operating at 5.8 GHz (ISM band).
In an experiment conducted to measure the complex permittivity for non-invasive RFmicrowave blood glucose sensing using a glucose-water solution of 1 - 4 g/dL glucose/water in
50l of deionized water, a shift in resonance frequency was observed. When tested in the
physiologically important 100 - 500 mg/dL range, no clear shift of resonance frequency was
recorded as the variation in the permittivity, εr, was too low [30]. The present research differs in
that the permittivity of the glucose-water solution in [30] ranged between 68 - 80 for the frequency
range 1 - 8GHz, while the present research is based on the real blood glucose level εr= 52.5 at
the frequency of 5.8 GHz and uses a human tissue model.
A single patch antenna model was proposed in [31] using an oil in water tissue mimicking
phantom over the frequency range from 0.3 - 20 GHz using a patch resonator operating at 2.4
GHz in the ISM band. The results of this research were similar to the research in [10], where two
antennas, wideband and narrowband, were designed to be sensitive to the dielectric variations of
the blood when placed in proximity to the human body. In a simulated layered tissue model, the
antenna’s resonant frequency increases with an increase in glucose. The current research differs
from [31] and [10] in that the human tissue model was used as a general approximation, and thus
does not pertain to any specific location of the body. In addition, the blood was simulated and/or
mimicked as a layer covering the entire surface of the phantom area rather than as a vessel
approximation which is closer to the human body situation.
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1.5 Contributions of Dissertation
The dissertation contributes in the following aspects:
1) Use of a finite blood vessel to mimic the human body, not a planar blood layer as in
previous studies.
2) Analysis of implantable antenna for passive and active sensing of blood glucose in the
abdominal thorax area by simulations in ANSYS EM15.0 HFSSTM.
3) Analysis of non-invasive sensing of blood glucose in the upper arm area by ANSYS
EM15.0 HFSSTM and experimental measurements using oil-in-gel phantoms. The
analysis determines a) the effect of lateral displacement of antenna from the blood
vessel on the results, b) the effect of the vertical elevation of the antenna sensor from
the outer surface of the skin, and c) the effect of other variations due to skin thickness
variations, blood vessel depth, and thickness variation of the fat.
4) A calibration system for optimal antenna sensing location is proposed that uses three
antennas in a diagonal position from each other.
5) A sensing system platform for measurement of blood glucose levels based on the noninvasive results of simulation and experimental antenna patch sensing in the upper
arm area.

1.6 Dissertation Summary and Organization
The dissertation is organized into five chapters. Chapter 1 presents an overview of
glucose monitoring, a review of existing approved self-monitoring glucose systems with their
associated challenges, and presents the motivation of this research as an alternative for a selfmonitoring glucose system. This chapter provides the problem statement, the research objective,
the positioning of the research within the field of glucose sensing, the contributions made to this
field and the dissertation organization.
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Chapter 2 gives an overview of the background information necessary to develop an RF
blood glucose sensing system. A human tissue model is presented based on human tissue
physiological and electrical properties for the abdominal area for the implantable active and
passive alternatives and for the upper arm area for the non-invasive alternative. This chapter
presents simulations for active and passive antenna sensors followed by the non-invasive
antenna simulations for ideal conditions.
Chapter 3 concentrates on the non-invasive sensing model, analyzing the effect of
misalignment of the antenna which includes shifting the antenna sideways away from the blood
vessel, and variations when the antenna is elevated above the skin from a reference 2 mm above
the skin position. Further simulations analyze variations due to skin thickness increase/decrease
and vein location depth. Experimental results are presented for the non-invasive sensing model
and analyzed in comparison with the simulation results. An antenna alignment calibration strategy
is presented to improve system accuracy.
Chapter 4 is an overview of a complete non-invasive blood glucose system. It presents a
blood glucose system and an electronic system platform to automatically compute the measured
shift in resonance frequency caused by variations in glucose levels digitally. The dissertation
finally concludes with Chapter 5 which summarizes the research during the dissertation and
presents future work which may be pursued to further demonstrate/improve the non-invasive
glucose measurement system described in this dissertation.
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CHAPTER 2: RF GLUCOSE SENSING

This chapter presents background information necessary for the design of a human tissue
model, including the electrical parameters and physiological considerations for the implantable
active antenna sensing model, implantable passive antenna sensing model and non-invasive
antenna sensing model. The chapter presents an electromagnetic simulation tool for simulations
of the antenna in free space, followed by simulations of the antenna embedded in human tissue
for both active and passive sensing, and ending by an antenna externally located facing human
tissue for non-invasive sensing.

2.1 Overview of Antenna Glucose Sensing Models
2.1.1 Implantable Active Sensing
In the implantable active sensing case, displayed in Figure 1, the antenna acts as an active
sensor. In this case, internal electronic circuitry and a power supply are needed for operation of
the glucose sensing system. This case could be ideal for a future implantable glucose sensor
that also automatically dispenses insulin in real time.

Figure 1: Active sensing antenna implanted in abdominal area configuration.
Implant requires circuitry and power supply. Reprinted with permission from [32] © 2016 [MRS]
1A

partial section of this chapter (text and figures) was published in MRS conference paper SiC RF
Sensor for Continuous Glucose Monitoring © 2016 [MRS]. Permission is included in Appendix A.
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2.1.2 Implantable Passive Sensing
In the implantable passive sensing model, as displayed in Figure 2, the antenna is
implanted in fatty tissue and two additional external antennas (a transmitting and a receiving
antenna) are required. The transmitting antenna sends a signal towards the implanted antenna,
which is reflected to the receiving antenna by the implanted sensor and thus ‘reads’ the sensors
resonance frequency. External circuitry records any glucose-induced changes in the implanted
sensor’s resonance frequency in addition to generating the required waveform.

Figure 2: Implanted passive sensing antenna and external antennas configuration.
The antenna implanted in the body does not require power supply or additional internal circuitry.
External transmit and receive antennas interrogate the passive sensor. Reprinted with
permission from [32] © 2016 [MRS]

2.1.3 Non-Invasive Sensing
A non-invasive solution would be much more convenient for the patient, would not require
surgery, and lower power WiFi communication would be allowed due to no signal attenuation in
human tissue. Figure 3 displays an antenna patch located above the upper arm. The antenna
and the external circuitry are located outside the body.

Figure 3: Non-invasive sensing antenna on top of the arm configuration.
The antenna and the electronic circuitry are located outside the body. The antenna is placed in
direct line of sight with a major vein.
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2.2 Glucose Dependent Properties of Blood
2.2.1 Permittivity and Conductivity of Blood
The concept of an implantable antenna being used as a glucose sensor is based on the
principle that the medium that surrounds an antenna affects parameters such as input impedance
and resonance frequency of the antenna due to glucose-dependent changes in blood permittivity
and conductivity. In the context of electromagnetism, permittivity is a measure of the resistance
encountered in the medium when forming an electric field. In other words, permittivity gives a
measure of the material’s ability to allow an electric field to be transmitted (or stored). The
dielectric constant of a material is the ratio of the permittivity of a substance to the permittivity of
free space. When exploring effects of any medium on electromagnetic waves, one can explain
the basis in terms of a frequency-dependent complex relative permittivity given by the formula:

ε=ε΄-jε”

(1)

where the real part of the permittivity, ε΄, defines the amount of electromagnetic energy
stored in a material relative to the amount stored in vacuum; and the imaginary part, jε”,
defines the loss factor or dielectric losses. This second term can also be expressed in
terms of the material conductivity as:
ε” =/ εO 

(2)

where  is the electrical conductivity of the material [33].

2.2.2 Blood Glucose Dependent Experiments
In an experiment conducted at the Pukyong National University and Kyungpook National
University, South Korea, it was observed that the real (ε΄) and imaginary (ε”) dielectric constants
of blood increases as the glucose levels in the solution decreases [34]. The experiment was
conducted on a hamster tail, where a correlation between blood glucose and ε΄ at a frequency of
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10 kHz was observed, while further experiments showed also a frequency and time dependence
for the results. The data collected resulted in the glucose dependence shown in Figure 4 below.

Figure 4: Water/glucose concentration dependence of the dielectric constant.
Graph shows the real (ε΄) (left) and the imaginary (ε”) part of equation (1) (right) at 10 kHz.
Reprinted from [34] © 2003, with permission from Elsevier.
Furthermore, the effects of sugar and salt on ε’ and were investigated with a skinmimicking gel, where the frequency dependence of the dielectric and conductivity constants are
shown in Figure 5 and Figure 6. Either sugar or salt was varied. As can be observed, the added
sugar, while keeping the salt constant, decreases the relative permittivity significantly, and
increases to a smaller degree the conductivity. Also, the added salt, while keeping the sugar
constant, decreases the relative permittivity to a small degree, and increases the conductivity
significantly.

Figure 5: Frequency dependence in blood gel as a function of sugar.
Permittivity dependence (left) and conductivity dependence (right) © [2008]IEEE. Reprinted
from [35] with permission grant found in Appendix C
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Figure 6: Frequency dependence in blood gel as a function of sugar.
Permittivity dependence (left) and conductivity dependence (right) © [2008]IEEE. Reprinted
from [35] with permission grant found in Appendix C

Human blood can be characterized by the Debye formula:
∆𝜀

𝜀 ∗ = 𝜀∞ + 1+𝑖2𝜋𝜈𝜏

(3)

or from an extension in the Havriliak-Negami formula:
∆𝜀

𝜀 ∗ (𝜈) = 𝜀∞ + [1+(𝑖2𝜋𝜈𝜏)1−𝛼 ]𝛽

(4)

from which the Cole-Cole model, where 0 ≤ ≤ 1 and =1, can be formulated [36].
Using in-vitro human blood samples, the dielectric properties of blood were correlated to
blood glucose using a modified Cole-Cole model [10]. In a study conducted by Topsakal et al. at
the University of Alabama Birmingham, the permittivity and conductivity of blood plasma was
measured in-vitro at different glucose levels from 0 mg/dl to 16000 mg/dl over a frequency range
from 500 MHz to 20 GHz. The results in Figure 7 display the relative permittivity and shows that
it is decreases as the frequency increases [27]. That is as the glucose levels increase, the
permittivity decreases. The results in Figure 8 [27] indicate that the electrical conductivity
increases as the frequency increases. Notice that, for lower frequencies, there is no significant
variation in the conductivity as the glucose level increases. For frequencies close to 10 GHz, the
conductivity decreases for higher frequency with the glucose levels.

14

Figure 7: Relative permittivity of blood plasma vs. glucose levels concentration
© [2008] IEEE. Reprinted from [27] with permission grant in Appendix C

Figure 8: Electrical conductivity of blood plasma vs. glucose levels concentration.
© [2008]IEEE. Reprinted from [27] with permission grant in Appendix C

Overall, experimental tests have shown that variations in blood glucose change the
permittivity and conductivity of the medium, indicating that an implantable antenna has a great
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sensing potential, as its characteristics change directly with these changes in the surrounding
medium, where the medium in the application is the blood glucose.

2.2.3 Sensing of Blood Glucose Levels with a 10GHz SiC Antenna
In tests conducted by Afroz et al. on a 10 GHz Silicon Carbide (SiC) based Ti/Au patch
antenna, it was shown that the resonant frequency of the antenna shifts as a function of glucose
level, as obtained based on in-vitro experimentation using synthetic blood fluid (SBF). A change
from 120 mg/dl to 530 mg/dl of blood glucose resulted in a 40 MHz shift that was fairly linear.
Assuming a linear change versus glucose concentration this translates to a shift of 97 KHz for
every 1 mg/dL change in blood glucose. Using a Vector Network Analyzer (VNA), the return loss,
S11, of the sensing antenna was measured. Using this method, it is easy to see the resonance
frequency of the antenna as this is the point where a minimum in RF signal energy is reflected
back to the VNA. Additional experiments using pig blood samples displayed a similar behavior.
The S11 response using synthetic blood and pig blood as a function of glucose level is shown in
Figure 9. A comparison of the relative resonance frequency shift using synthetic blood and pig
blood samples is displayed in Figure 10 [28] [23].

Figure 9: Return loss of a 10GHz antenna for various blood glucose concentration.
Measured in synthetic blood (left) and pig blood (right) for (a) 67 mg/dl, (b) 120 mg/dl, (c) 270
mg/dl, (d) 490 mg/dl [23]. Note that fO shifts to lower frequency as the glucose concentration
increases. © [2008]IEEE. Reprinted from [28] with permission grant in Appendix C
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Figure 10: Resonance frequency vs. glucose concentration of a 10 GHz SiC antenna.
The colored regions denote healthy (green) and unhealthy (blue) levels of blood glucose in
humans and was added for reference. Note the roughly linear change in fO vs. frequency. Trend
line is a least-squares fit of the measured data © [2008]IEEE. Reprinted from [28] with
permission grant in Appendix C
2.3 Human Tissue Models
2.3.1 Electrical Parameters for Each Human Tissue
The electrical parameters for human tissue used in this research were established using
[37], which is based on the parametric model for the calculation of the dielectric properties of body
tissues [33, 38]. Table 2 shows the conductivity and permittivity for human tissues of interest.
Table 2: Conductivity and permittivity of human tissues at 2.4, 5.8 and 10GHz [37].
Human Tissue

Conductivity

Permittivity

2.4GHz

5.8GHz

10GHz

2.4GHz

5.8GHz

10GHz

Wet Skin

1.5618

4.342

8.951

42.923

38.624

33.528

Fat

0.10235

0.29313

0.58521

5.2853

4.9549

4.6023

Blood

2.5024

6.5057

13.131

58.347

52.539

45.109

Muscle

1.705

4.9615

10.626

52.791

48.485

42.764

As the frequency increases, the permittivity value decreases and the conductivity value
increases. The permittivity of fatty tissue is much lower than the permittivity of muscle, being an
additional reason why the sensor is proposed to be implanted in the fatty area (i.e., less antenna
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loading from the surrounding tissue). At the selected frequency of 5.8 GHz, the permittivity of
muscle is 48.485, while for fatty tissue, it is 4.9549. To define the electrical properties of blood,
the calculations by [27] and [39] were used in the models for implantable active sensing and noninvasive sensing along with the values provided in Table 2 [33, 40, 37].

2.3.2 Human Tissue Model for Active and Passive Implantable Sensing
2.3.2.1 Location in Human Body
In-vitro experimental results with a 10 GHz 4H-SiC based antenna placed under both
muscle and fat concluded that the best implant location is in the fatty tissue layer [23]. The
simulations for the active and passive implantable sensor were modelled within the fatty tissue
layer of the abdominal area as displayed in Figure 11, which displays a front abdominal area cross
view and the proposed location of the sensor implant (blue bar on left side of image). This follows
the current guidelines for needle insertions, which avoid the areas around the belly button and
the areas where the body naturally bends [41]. The simulation considered that the implant would
be within the fatty tissue layer in proximity of the superficial epigastric vein, due to veins being
less muscular than arteries and located closer to the surface of the tissue than arteries. The
implanted patch antenna would be facing the muscle and blood. Included in the model are the
skin, fat, muscle and blood.

Figure 11: Proposed implant position in the fatty area of the front abdominal wall.
Front wall of the abdomen horizontal cross-section view. The sensor implant is displayed as a
blue bar to the left in the fat layer.
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2.3.2.2 Thickness Approximations of Human Tissue
Based on the evaluation of glucose levels from adults with diabetes and diverse
demographic backgrounds, the average skin thickness is 2.2 mm [40]. The average abdomen
subcutaneous adipose layer thickness, which will be referred to by its common term as fat, was
13.9 mm in the abdominal area, ranging from 13.2 mm to 17.7 mm [40]. In a study to characterize
changes in muscle thickness in the transverse abdominis (TrA) and internal oblique (IO) muscles
during common exercises, the muscle thickness was obtained at rest with the subjects in the
supine position with their knees bent at 90º. The average transverse abdominis muscle was
0.50±0.11 mm thick for males and 0.43±0.11 mm for females, and the average thickness for the
internal oblique muscle was 1.09±0.23 mm for males and 0.73 ±0.16 mm for females [42]. There
is an increase in the thickness of the transverse abdominis and the internal oblique related to the
type of exercise being executed, in thickness ratio (contracted/rest ratio) that ranges from 1.88 ±
0.52 to 1.118±0.22 [42].

2.3.2.3 Human Tissue Model for Implantable Sensing
Figure 12 shows a human tissue model for implantable sensing used for the implantable
active sensing, as is, and for the implantable passive sensing by adding the external antennas in
the air section (not shown for clarity).

Figure 12: Human tissue model for implant showing the thickness and εr of each layer.
The antenna position is shown at a distance d from the blood layer. (Drawing not to scale).
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2.3.3 Human Tissue Model for Non-Invasive Sensing
2.3.3.1 Location in Human Body
The location for the proposed non-invasive sensing approach is the upper arm location, in
direct line of sight of the cephalic vein, as displayed in Figure 13.

Figure 13: Antenna patch location over the arm showing cross sectional anatomy.
The target blood vessel is the Cephalic vein due to its proximity to the skin.
The figure is adapted from a video from The New England Journal of Medicine [43], ©
Masachussets Medical Society. Permission grant found on Appendix E.

2.3.3.2 Thickness Approximations of Human Tissue
The skin mean thickness for adults 25 years and older is 2.48mm for males and 2.4mm
for females while the mean arm subcutaneous thickness is 9.07mm for males and 12.01mm for
females [44].

For purposes of the simulations, the thickest rounded value for skin and

subcutaneous thickness were selected.
Two possible veins where evaluated: the cephalic and the basilic veins, both being large
superficial veins located in the upper limb. The network of veins varies person to person, and
thickness varies from different arms and different sections. The following measurements of
average basilic and cephalic vein diameter were used for the thickness values of the human arm
model. The cephalic vein has an average diameter of 1.8mm located in the superficial fascia on
the surface of the bicep’s brachii muscle [45]. The basilic vein is located deeper normally
perforating the deep fascia above the medial epicondyle. In Brazilian cadavers, the average
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diameters are shown in Table 3 [46]. Although the diameter of the basilic vein is more suitable
for testing, due to the deeper location of the vein, the cephalic vein was chosen for the model
used in this research.
Being that the cephalic vein was selected for the model, the muscle is based on the bicep’s
brachii muscle. This muscle varies from gender and the bodybuilding level of the individual. In a
study conducted taking the cross sectional area of the biceps of 585 subjects (342 males and 243
females), the average cross sectional area of the bicep was 22.2cm2 for males and 14.0cm2 for
females [47]. Another study, which aimed to study the muscle thickness changes following bench
pressing training, found the average thickness to be 25.1mm for males aged 25 years [48]. In a
study by Miyatani et al. comparing the measurement taken by ultrasound and by magnetic
resonance imaging (MRI), the bicep muscle thickness for males ages 23 to 40 was found to be
an average of 33mm when measured by ultrasound and 32mm when measured by MRI [49].
When structuring the arm tissue model, other factors where considered such as lower muscle
thickness for females, as well as arm position and movement that affect muscle tension, and age.
These were all implemented as variables. The muscle thickness used in the model was 25mm.
Table 3: Human arm model physical dimensions.
Human
Tissue
Skin
Fat
Cephalic
Vein
Basilic
Vein

Biceps
muscle

Measure
[mm]
2.48
2.4
9.07
12.01
1.8

Description

Model

Thickness for male
Thickness for female
Thickness for male
Thickness for female
Mean diameter

2.48mm

1.90±0.63
2.24±0.73
3.26±1.15
3.46±1.41
4.96±1.84
5.09±1.28
32-33mm

at the fold of the cubicus.
Right arm
Left arm
at midpoint fold
Right arm
Left arm
Inferior border of the teres major muscle.
Right arm
Left arm
Average thickness for male 23-40 years old

25.1mm

Average thickness following bench pressing male age 25
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12.01mm
1.8mm
Not used

25mm

2.3.3.3 Human Tissue Models for Non-invasive Sensing
Based on the human tissue physiology presented, the human tissue model for noninvasive sensing was setup as a layer of skin on top of a layer of fat and then a layer of muscle.
Within the fat layer a cylindrical tube represents the target blood vessel. The dimensions were
set according to Table 3. The model was used in all simulations for non-invasive blood glucose
sensing, and will be referred to as the complete human tissue model (HTM). The top view and
side views of the model are displayed in Figure 14. The simulations for non-invasive blood
glucose sensing system are also later repeated using a simplified human tissue model (SHTM),
in which the skin and muscle layers are disregarded, and only blood vessel and fat are taken into
consideration, to determine the effect these layers on the results. The side views of this second
model are displayed in Figure 15.

Figure 14: Complete human tissue model for non-invasive sensing simulations.
Side view in the XY (left top), YZ (right top) plane and top view (bottom) showing antenna above
the HTM. Antenna spacing above the arm tissue model was 2 mm.
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XZ Plane (side view)

YZ Plane (side view)

Figure 15: Simplified human tissue model for non-invasive sensing simulations.
Side views showing the cephalic vein within the fat tissue. No skin and muscle included in this
model. Left vein oriented into the plane of the paper, right parallel, as shown.

2.4 Electromagnetic Simulation Setup
2.4.1 HFSS™ Overview
High Frequency Electromagnetic Field Simulation (HFSS™) from Ansys is a finite element
method solver software tool useful for simulating 3D electromagnetic structures [50].

The

software can accurately characterize an antenna’s performance in free space as well as its
performance when modeled surrounded by the human tissue layer, and the effect of the presence
of any additional antennas in close proximity. Each human tissue layer is modeled electrically
with a corresponding electrical permittivity and conductivity as previously described. Details of
the antenna’s dimensions and design variables are described in the following chapter. The next
section describes the PML (Perfectly matched layer) used in HFSS to prevent non-physical
resonances during simulation and the antenna performance plot setup used during the
simulations.

2.4.2 PML Boundaries
Perfectly matched layer (PML) boundaries were setup for each boundary layer of the
human tissue model in order to absorb any EM radiation thus resulting in no, or minimal, EM
reflection, from the simulation boundaries. The perfectly absorbing layer simulation is necessary
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in the modeling of the glucose sensor so that no reflected waves are present in the area under
study since the SiC RF antenna sensor is a resonant structure. PML Boundaries were setup with
a uniform layer thickness of 15 mm, and with a propagation constant 𝑘 = 𝜔√𝜇𝜀 at minimum
frequency of 4 GHz. This results in the following setup according to the human tissue permittivity
values reported in Table 2 result in the k constant as shown in Table 4.
Table 4: Propagation constant of each layer of human tissues
Human Tissue
Muscle
Fat
Skin
Blood permittivity*

Calculations for propagation constant
𝒌 = 𝝎√𝝁𝜺 (1/m) at 4GHz

Propagation constant k

4 ∗ 109
√48.485
3 ∗ 108

583.045

4 ∗ 109
√4.955
3 ∗ 108

186.389

𝑘 = 2𝜋

4 ∗ 109
√38.624
3 ∗ 108

520.387

𝑘 = 2𝜋

4 ∗ 109
√52.539
3 ∗ 108

606.931

𝑘 = 2𝜋

𝑘 = 2𝜋

*Average blood glucose level. This was varied.

In Figure 16(a), the human tissue model is shown in 3D view without the PML layer, and
in Figure 16(b) with the PML layer which was set for each tissue layer so as to absorb any stray
radiation and eliminate reflections back to the sensor zone.

a)

b)
Figure 16: Human tissue model with (a) no PML boundary and b) with PML boundary.
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2.5 Antenna Design for ISM Band (5.8 GHz) in Free Space
2.5.1 Antenna Design Overview
The antenna was designed using a 635µm thick Rogers 6010 substrate (𝜀r=10.2, tan δ =
0.0023). It was designed for free space using HFSSTM Antenna Design Kit for a rectangular patch
antenna that is probe fed. The desired frequency of 5.8 GHz, and the characteristics of the
material, were input into the software. This design was simulated in Ansoft EM15.0 HFSSTM
adding the human tissue model for the implantable option and for the non-invasive CHTM and
SHTM tissue models. The length, width and location of the antenna feed were gradually modified
to optimize the design for the antennas implanted in the active and passive sensing models, as
well as for the non-invasive mode where the antenna was found to operation best when placed 2
mm from the arm’s surface.
The free-space (no tissue load) design dimensions of the antenna patch at 5.8 GHz are
shown in Figure 17. The antenna design was performed to optimize the antenna’s performance
by varying both the patch dimensions and feed position.

(a)

(b)

(c)

Figure 17: Schematic top and cross section views of the SiC RF antenna.
(a) top view, (b) cross-section view XZ plane and (c) cross section view YZ plane.
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2.5.2 Optimizing the Antenna to Resonate at 5.8 GHz
The antenna patch’s dimensions were set to subX=2.4 cm, subY=1.9 cm, subH=10 mil,
px=0 mm, patch X=8.8 mm and d=2 mm. The parameters patchY, and py, were varied one at a
time to optimize the antenna resonance to 5.8GHz (i.e., minimum return loss S11). Figure 18
shows the resulting predicted S11 value as the patchY parameter changes from 7 mm to 7.2 mm.
This variation of the resonant frequency, in correspondence with the patchY size, is plotted in
Figure 19.

Figure 18: Simulated antenna in free space to optimize operation at 5.8 GHz.
Variables are fixed at Patch X=8.8mm, px=0mm and py=1.2mm. PatchY is varied.

Figure 19: Plot of simulation data showing variation in fO vs. the variable Patch Y.
Dotted line is a least-squares linear fit to the data.
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The parameter py was varied from 0 to 1.6 mm. Simulated S11 results are displayed in
Figure 20. As the displacement of the feed increases, the S11 resonant frequency, gain and
bandwidth increase. For instance, a py of 0.9mm resulted in a resonant frequency of 5.74 GHz
and S11 of -11.9 dB. For py at 1.2 mm the resonant frequency increases to 5.79 GHz and S11 of
-35.2 dB. Increasing py to greater than 1.2 mm results in a significant decrease in S11 as the
displacement of the feed is located outside the dimensions of the patch. For all further trials, py
was set to a fixed value of 1.2 mm.

Figure 20: Simulated data showing variation of S11 based on the location of feed py.
The displacement feed dimension py increase results in a decrease in frequency and decrease
of the dB minimum peak when the value is less than or equal to 1.2mm.

The final parameters of the antenna design in free space at 5.8 GHz are displayed in Table
5. In summary, the free space antenna for 5.8GHz is designed on a 25 mil thick Duroid substrate
2.4x1.9cm with a rectangular patch 8.9 x 7.2mm. The inset feed displacement is 1.1mm in the y
axis and is centered in the x axis.
Table 5: Antenna patch dimensions for free space operation at 5.8 GHz
Parameter
subX
subY
patch X
patchY
subH
px
py
Dimension

2.4 cm

1.9 cm

8.9 mm

7.2 mm
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25 mil

0.0 mm

1.1 mm

The simulated value S11 for the antenna in free space and corresponding beam profiles
can be observed in Figure 21 and Figure 22.

Figure 21: Final free-space antenna design showing simulated resonance at 5.80 GHz.

Figure 22: Simulated antenna beam profile of final optimized antenna.
(a) realized gain result (left)and (b) total gain result (right)

2.6 Antenna Design for Active Sensing Mode
2.6.1 Antenna Design Overview
For the simulations presented in this section, the antenna is implanted in the fatty layer
between the skin and blood/muscle with a spacing “d” as shown in Figure 12. The antenna patch
is facing the blood/muscle tissues.
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The average relative blood permittivity was set to 62.5 and a blood bulk conductivity of 7.5
Siemens/m was used. The other tissue values were set to the fixed permittivity displayed in Table
2. The antenna was matched to the feed by changing the location of the feed and the dimensions
of the antenna following the same procedure used to optimize antenna resonance in free space.
Then, the simulated blood relative permittivity was varied in steps of 0.2 from 62 to 63.6, while
the bulk conductivity remained at the fixed value of 6.5 Siemens/m. The reason for this being that
blood permittivity varies as the glucose levels in the blood varies, but experiences a nonsignificant variation in bulk conductivity [23] [10].

2.6.2 Antenna Matching to Tissue Environment
2.6.2.1 Varying the Parameter Py
The parameter py, which is the distance of the location of the feed from the center point
(px=0, py=0), was varied between py=1.4 to 1.5. The greater the distance py, the higher the
resonant frequency. Also, the resonance increases and the bandwidth decreases, as can be
observed from Figure 23 and Figure 24. Note that patchX was set to 4.1mm and patchY to
7.1mm.

Figure 23: Return loss of active antenna based on py variation.
Optimizing the active mode antenna by displacement of feed py distance.
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Figure 24: Resonant frequency and gain of active antenna based on py variation.
(a) Variation of frequency vs. the feed py distance plot (left) and (b) variation in the gain vs. feed
py distance. Trend line is a least squares fit to the data (right).

2.6.2.2 Variation of Parameter PatchX.
Increasing the dimension patchX increases the resonant frequency and decreases S11.
The parameter py was set to 1.4mm and patchX was varied from 4 mm to 4.5 mm. Figure 25 and
Figure 26 show the computed return loss S11 versus variation in patchX. The optimized value of
Patch X is 4.1 mm, as it approximates to the desired 5.8GHz and has a deeper peak than values
above 4.1 mm.

Figure 25: Return loss of active antenna based on patchX variation.
The optimized value of PatchX is 4.1 mm.
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Figure 26: Resonant frequency and S11 of active antenna based on patch X variation.
(a) Variation of frequency vs. the distance patchX distance plot (left) and (b) variation of return
loss minimum vs. distance patchX distance(right). Trend line is a least-squares fit to the data.

2.6.3 Resulting Antenna Dimensions
Assuming a blood permittivity of 62.5 and referring to Figure 17, the antenna dimensions
are as described in Table 6.

Parameter

Table 6: Antenna dimensions for implantable antenna
subX
subY
patch X
patchY
subH
px

Py

Dimension

2.4 cm

1.4

1.9 cm

4.1 mm

7.1 mm

10 mil

0.0 mm

The result of the single implanted antenna facing muscle is shown in Figure 27:

Figure 27: S11 of the optimized implantable antenna.
Note that the resonant frequency used in this design was 5.77 GHz.
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2.6.4 Effect of Glucose Levels in Blood
The optimized antenna in human tissue was simulated by varying the relative permittivity
of blood from 62 to 63.6, while the bulk conductivity remained at the fixed value of 6.5 Seimens/m.
The S11 results in Figure 28 show a shift in resonant frequency as the blood permittivity changes,
as expected based on previous results in the literature [23].

Figure 28: Simulated S11 of antenna in human tissue results in a shift of resonant frequency as
blood permittivity varies.

Plotting frequency versus blood permittivity in Figure 29, one can observe that as blood
permittivity increases, the frequency increases via an approximate second order equation as
shown in the figure (i.e., polynomial fit).
5.78
5.778
y = 0.0069x2 - 0.8564x + 32.435

fo [GHz]

5.776
5.774
5.772
5.77
5.768
5.766
5.764
61.5

62

62.5

63

63.5

64

Blood relative permittivity

Figure 29: Plot of simulated resonant frequency vs. blood permittivity of the antenna.
Note that the dependence roughly follows the polynomial fit displayed in the figure.
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2.6.5 Summary of Active Sensing Antenna Design
The single antenna design simulated in the fatty tissue facing blood and muscle was
optimized for an average blood permittivity of 62.5 by variation of the antenna’s dimension and
location of the feed distance py.

The resulting antenna dimensions were: subX=2.4cm,

subY=1.9cm, subH=10mil, patchX=4.1mm, patchy=7.1mm, px=0mm, py=1.4mm, for a distance
from the antenna to the blood tissue layer of 2mm. The blood permittivity was varied from 62 to
63.6 in steps of 0.2 using a discrete sweep, resulting in a total frequency variation for this range
from 5.7655 to 5.7778, respectively. In total, for this range of blood permittivity, the frequency
variation was 12.3 MHz, corresponding to a 500mg/dL glucose variation. Since an increase of
glucose level in blood decreases its permittivity, it can be concluded that at greater glucose levels,
the resonant frequency will be lower. The antenna design can be used for an active sensing
system as displayed in Figure 1. To further continue this path of research, a corresponding sensor
platform to both drive the antenna and measure any glucose-dependent shift in resonant
frequency is necessary. This will be discussed in Chapter 4.

2.7 Passive Sensing Simulations
2.7.1 Overview of Passive Sensing System
The passive sensing system has been simulated in the same human tissue model (Figure
12) described for the antenna active sensing system. However, in this case, the sensing antenna
simulated needs to be dual sided, facing both the muscle with one side for sensing purposes and
the skin and external antennas with the other side for communication purposes. As was described
in Figure 2, the overall passive sensing method requires an implanted antenna in human tissue
and two additional antennas located external to the body to complete the system.

In the

simulation, the two additional external antennas are in the air box section of the model. Figure
30 shows the antennas of the system located in the human tissue model.
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Figure 30: Passive sensing requires an implantable antenna and two external antennas.
The implanted antenna is dual sided and located is in the fatty tissue. The external antennas
are located external to the human tissue in the air.

This analysis of the system was done by parts: The external antennas are simulated
individually and S11 was recorded, followed by the external antennas simulated together to record
the coupling between them. During this analysis the antenna separation distance was varied. To
design the dual sided antenna, two parts were required: an antenna design for the side facing the
blood and muscle, which coincides with the active sensing antenna function, and an antenna
facing the external area, which interacts with the external antennas. This latter part is further
evaluated. A summary of the passive sensing system was evaluated through simulation and is
now discussed in detail.

2.7.2 Single External Antenna
The external antennas were simulated individually, located 2mm from the skin as
displayed in Figure 31. Note that both antennas have the same dimensions, therefore yield same
S11 result. The simulated value of S11 of the optimized external antenna is displayed in Figure 32.
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This parameter was used as a reference level of the external antenna S11 to human tissue without
the effect of other external or internal antennas present.

Figure 31: Simulation setup with one external antenna only in the air space.
The external antenna is placed 2 mm above the skin layer, as shown.

Figure 32: Simulated S11 for external (or internal) antenna only.
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2.7.3 External Antennas Tx and Rx
The external antennas were simulated simultaneously to obtain the effect that the
antennas have on each other, by recording their S11 and S21 parameters, and analyzing the results
versus the separation distance between the antennas sep_d=1mm, 10mm and 20mm; keeping
the distance of 2mm from the skin. The solutions of S11 and S21 (return and insertion loss) for
both the external and internal antennas facing the human tissue, and without the embedded
antenna as set up in Figure 33, are displayed in Figure 34 and Figure 29, respectively. The S21
levels for this simulation was our reference point for subsequent simulations.

sep_d = separated distance

Figure 33: Simulation model for both external antennas separated by 1, 10 or 20mm.

sep_d = separated distance

Figure 34: S11 for external antenna setup of Figure 33, for sep_d= 1,10 and 20mm.
Note the optimum return loss to the largest spacing of 20mm.
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Figure 35: S21 for external antenna setup of Figure 33 for sep_d=1, 10 and 20mm.
As expected the largest value of S21 corresponds to the largest separation between the
antennas (i.e., 20 mm).

2.7.4 Implantable Antenna
The passive system utilizes an embedded antenna that has two qualities: 1) Has blood
glucose sensing potentiality, and 2) this variation must be detectable by the external antennas.
This section describes the antenna as a blend of two antennas, each with the quality described.
For the antenna to have the first quality, the sensing potentiality, it must have a characteristic
similar to the active antenna, in which the resonant frequency of an antenna patch varies in
correlation with the variation of the electrical properties of the blood (permittivity and electrical
conductivity). For this to work the antenna patch of this antenna must be facing the muscle and
blood. Note that this is the antenna described in the active sensing section. For the antenna to
have the second quality, detectable by external antennas, the signal incoming from an external
antenna must be reflected in this implanted antenna into the second external antenna. For this
aspect, the antenna must be facing the external antennas. Therefore, the passive antenna must
have a combination of the two requirements: an antenna facing the muscle to detect variations of
the blood glucose, and an antenna facing the external antennas, to interact with external
antennas, as displayed in Figure 36.
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Figure 36: Implantable antenna as a two single sided antenna with two functions.
The implant must both detect variations of blood glucose levels and 2) communicate with the
external antennas.

2.7.4.1 Sensing Properties
The dual sided antenna facing the muscle and blood senses the blood glucose levels by
correlation between shift of resonant frequency and the variation of the blood glucose levels, as
for the active sensor discussed previously. Figure 37 displays the partial embedded antenna
model that has sensing potentiality. Notice this partial passive antenna is the model used for the
active antenna.

Figure 37: Partial implanted antenna must detect glucose variations.
Note that this is the antenna designed in the active sensing mode.
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2.7.4.2 Communication with External Antennas
The external Tx antenna sends a signal to the implanted antenna, which must be reflected
back to the receiving antenna Rx. Therefore, the main lobe of the antenna patch must be in the
direction of the external antennas, as displayed in Figure 38.

Figure 38: Partial implanted antenna must communicate with the external antennas.
Tx excites the sensor patch and Rx reads the corresponding shift in resonance frequency due to
glucose variations.

To analyze the antenna setup they were first tested in free space with and without the
passive antenna, and the results are summarized in Figure 39.

Figure 39: Simulated S21 results of passive sensing antenna setup in free space.
Simulation with the passive antenna (solid curves) and without (dotted curves).
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Analyzing the S21 of external antennas with and without the passive antenna implanted in
human tissue, it was concluded that a separation distance of 1mm was too close. There is high
mutual coupling between the external antennas for this separation distance. The S21 was around
-18dB without the implanted antenna while the implanted antenna decreases S21 by ~ 1dB
between the implanted antenna and no antenna. A separation distance of 20mm between the
external antennas was too far from the reflecting signal. The S21 was around -33dB without the
implanted antenna, and improves by ~ 3dB with the implanted antenna present. The separation
distance between external antennas was 10mm. The S21 varies from ~-22dB to -28dB with the
implanted antenna, with ~ a 5dB variation between the implanted antenna and no antenna.
To analyze the communication of the implanted antenna with the external antennas in
human tissue, the simulation was performed by parts to obtain the effect of each individual part.
The first analysis was for an embedded substrate with an integral ground plane in the fatty tissue
at 2mm and at 7mm from the blood block with the external antennas separated by 1mm, 10mm
and 20mm. As a reference point, the solution where two external antennas were located outside
the body without any implant was used for this and all other subsequent analysis. In the next
analysis, a patch was added to the embedded substrate with ground, maintaining all other
parameters. Then, the feed was added while maintaining all other parameters. Finally, all
parameters were maintained, removing the feed of the embedded antenna, but leaving the
perforation for the feed.

2.7.4.2.1 Effect of Embedded Substrate and Ground
In the first analysis by parts, the simulation was performed with the following setup. A
substrate with ground embedded in the fatty tissue layer at 2mm (Figure 40a) and 7mm (Figure
40b) from the blood block were added to the previous setup of the external antennas separated
by 1mm, 10mm and 20mm (Figure 33). This was done to compare the effect of the implanted
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substrate on S21 of the external antennas. For an average fat thickness of 13.9mm, at 2mm from
the blood (Figure 40a), the substrate was located 11.9mm from the skin. At 7mm from the blood
(Figure 40b), the substrate was located at 6.9mm.

Figure 40: External antennas and embedded in fat substrate with ground plane model.
Implant at a) 2mm and b) 7mm from blood.

The S21 of the external antennas were compared when there was no implant (dotted lines),
and when there was an implant with a ground plane 2mm from the blood layer (dashed lines) in
three cases: external antennas separated by 1mm (green), by 10mm (red) and by 20mm (blue).
For frequencies lower than approximately 5.9GHz, the S21 of the external antennas when there
was an implant was higher than the cases where there was no implant in the body by 1dB to 4dB,
depending on the separation distance of the external antenna (Figure 41).

Figure 41: Simulated S21 of external antennas with internal substrate with a ground plane at
2mm from blood / muscle layer.
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In Figure 42, the S21 of the external antennas is compared when there was no implant
(dotted lines), and when there was an implant with a ground plane placed 7mm from the blood
layer (short dashed lines) for the same three cases as before: external antennas separated by
1mm (green), by 10mm (red) and by 20mm (blue). For the case of the antennas being separated
by 1mm, and for frequencies less than approximately 5.8GHz, the S21 of the external antennas
when there was an implant is higher than the cases where there was no implant in the body by
around 2dB. For the case of the antennas being separated by 10mm, the S21 of external antennas
the when there is an implant is higher than the cases where there is no implant in the body by
8dB to 10dB for frequencies between 5.5GHz and 5.9GHz. For the case of the antennas being
separated by 20mm, the S21 of the external antennas the when there was an implant was higher
than the cases where there was no implant in the body by 8dB to 12dB for frequencies between
5.5GHz and 5.9GHz.

Figure 42: Simulated S21 of external antennas with internal substrate with a ground plane at
7mm from blood / muscle layer.

All three cases have been graphed separately: When the external antennas have been
separated by 1mm (Figure 43), by 10mm (Figure 44 ) and by 20mm (Figure 45), where S21 with
no implant (dotted line) is compared to S21 with implant at 2mm from blood (dashed) and with S21
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with implant at 7mm from blood (short dashed). When the antennas are separated by 1mm, at
5.8GHz all S21 results have less than 1dB difference for the case there is no implant, approximate
to -12dB, for when the implant at 2mm from the blood and for when the implant is at 7mm. When
the antennas are separated by 10mm, at 5.8GHz all S21 varies from -23dB (at 7mm) to -28dB (at
2mm), to -32dB (when there is no implant).

Figure 43: Simulated effect of implanted substrate on S21 of external antennas separated by
1mm.

Figure 44: Simulated effect on implanted substrate on S21 of external antennas separated by
10mm.
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Figure 45: Simulated effect of implanted substrate on S21 of external antennas separated by
20mm.

Figure 46 shows a summary of the external antenna S21 dB for three cases: no implant,
implant in the fatty tissue 2mm from the blood (at 11.9mm from the skin) and implant 7mm from
the blood (at 6.9mm from the skin). Here we can observe that when the antennas are separated
by 1mm, an implant has little effect on the results. Having the antennas separated by 20 mm, S21
is too low to be useful for this application. .

Figure 46: Comparison of the simulated S21 [dB] of the external antennas at 5.8GHz as a
function of their separation and in relation to the internal implant position.
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2.7.4.2.2 Effect of Embedded Patch, Substrate and Ground
In the next analysis by parts, as shown in Figure 40, a patch antenna was added to the
implanted substrate of the previous section (Figure 40).

Figure 47: Configuration with implant in fat layer 2mm and 7 mm from the blood layer.
Implant composed of substrate, ground plane and patch antenna.

Figure 48 and Figure 49 show the effect of the patch on substrate implant on the external
antenna performance. The difference between the case in which the substrate and ground is
implanted and the case in which the patch, substrate and ground is implanted is less than 1dB
when this implant is located 2mm from the blood (Figure 48) and not noticeable when the implant
is located 7mm from the blood (Figure 49).

Figure 48: Effect on the S21 of external antennas of adding patch on implanted substrate and
ground at 2mm from blood layer.
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Note that at a 7mm distance,
no difference is observed.

Figure 49: Effect on the S21 of external antennas of adding patch on implanted substrate and
ground at 7mm from blood.

2.7.5 Passive System Simulations with Varying Blood Glucose Levels
Earlier it was noted that the implant was essentially two antennas on a single substrate: a
sense antenna, identical in function to the active sensor discussed earlier, and a second antenna,
on the opposite side of the implant, to interact with the external antennas. This embedded dual
sided antenna was modeled in HFSS with a 10 mil top and a 50 mil bottom substrate. As
previously described the top patch, located on the 10-mil substrate, is facing the blood and
muscle. This dual sided antenna embedded in fatty tissue with the two external antennas
configuration is shown in Figure 50 (side view) and an angular view in Figure 51.
The implant is located at 2mm from the blood to have the sensitivity required to experience
a shift a resonant frequency depending on the blood glucose level, according to previous results.
The external antennas are separated by 1mm. With this final setup, the simulation was performed
for a blood permittivity of 62.5 and repeated with a blood permittivity of 63.6 as shown in Figure
52. With no passive antenna, the simulated S21 is approximately -13dB but, unfortunately, varies
within a negligible range when the blood permittivity varies from 62.5 to 63.6. Using a passive
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antenna, S21 varies from approximately -11.85 for a glucose level of 63.6dB to approximately 12dB for a glucose level of 62.5dB at a frequency 5.8GHz and no significant shift of resonant
frequency is observed.

Figure 50: Passive dual antenna system as modeled in HFSS - side view.

Implanted antenna

external
antennas

Figure 51: Three antennas passive system as modeled in HFSS - angular view.
Bottom antennas in air layer which dual-sided implant is located in the fatty layer as shown in
side view previously.
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Figure 52: Passive antenna effect on S21 of external antennas vs. blood permittivity.
Simulated with blood εr = 62.5 and εr =63.6 . Fat simulated as free space as in preliminary test.
Note negligible change in S21 vs. permittivity indicating that this sensing approach is not worth
further consideration.

While the concept of a two-sided implant was initially thought to be a viable option for this
application, the simulation results presented here do not motivate further exploration of this
technique. This was somewhat surprising as results for an active implanted antenna were quite
compelling. Clearly a hybrid ‘active implanted, external sense’ antenna system does not appear
feasible for this application and was abandoned at this stage of the research.

2.7.6 Summary of Passive Sensing Design
Simulations for passive sensing were performed in parts in order to understand the
individual contribution of the dual-antenna implant. First, the external Tx (or Rx) antenna was
independently simulated in the air facing the human tissue model and, later, both antennas were
simulated versus a separation of 1mm, 10mm and 20mm to predict S21 when no implant was in
the body. This result served as a reference for the next simulations when various aspects of the
dual-antenna implant was added to the simulation. Afterwards a substrate implant with a ground
plane was implanted in the fatty tissue at 2mm from the blood (or 11.9mm from the skin) and at
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7mm from the blood (or 6.9mm from the skin). When the antennas were separated by 1mm, the
implant affects the S21 by less than 1dB at around the -12dB level. Having the antennas separated
by 20 mm, although the implant at 7mm from the blood layer affects the signal by about 10dB,
S21 was around -40dB. In conclusion, although there was less effect by having the antennas
separated by 1mm, this separation distance allows a stronger interaction with the implant, so this
was the separation distance used for the rest of the simulations. To finalize the simulations, a
completely passive approach was simulated, with a dual-sided antenna implanted in the fat and
the external antennas separated by 1mm. Varying the blood permittivity from 62.6 to 63.6 causes
a shift of S21 of less than 1MHz, which is basically negligible for this application.

Further

simulations and would need to be carried out to have conclusive results on the passive sensing
option for glucose sensing but, based on these observations, this approach was abandoned at
this stage of the research in favor of the non-sensing approach which is described next.

2.8 Non-invasive Sensing Simulations
2.8.1 Overview of Non-invasive Sensing
For the non-invasive blood glucose sensing system, simulations were performed using the
human arm tissue model described earlier in Figure 14. The antenna was designed by initially
taking the single external antenna designed to function in free space, optimized to face the human
tissue model, by optimizing the antenna geometry via parameters py, patchX and patchY. The
distance from the skin from 0mm (antenna touching the human skin) to 3mm above the skin, in
intervals of 0.5mm, was studied and the antenna optimized for each spacing studied. It was
observed that the optimum spacing was 2 mm. Therefore all further tests were carried out 2mm
above the skin, and aligned with the blood vessel using the average human tissue skin and fat
thicknesses, as well as blood vessel depth. The antenna’s dimensions of the substrate and patch
and the separation distance of the feed used are listed in Table 7.
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Table 7: Antenna dimensions for non-invasive blood glucose sensing.
Parameter

subX

subY

patch X

patchY

subH

px

py

Dimension

2.4 cm

1.9 cm

3.7 mm

7.9 mm

25 mil

0.0 mm

1.5

2.8.2 Effect of Variation of Blood Vessel Electrical Permittivity
Using the external antenna optimized to the tissue model described in the last section,
simulations of the antenna response as a function of blood glucose level were conducted. The
blood vessel permittivity in the model was varied from 51.397 to 52.642 and the resulting return
loss, S11, was as shown in Figure 53.

Note that the resonant frequency shifts with blood

permittivity (i.e., glucose) which indicates that this sensor modality is worthy of further exploration.

Figure 53: Variation of blood permittivity vs. return loss for non-invasive antenna.
Note the predicted shift in resonant frequency, fO, as a function of blood permittivity (i.e.,
glucose) thus motivating further study of this sensing approach.

In this permittivity range, a shift in the resonant frequency of 10MHz was observed. An
increase of blood permittivity resulted in an increase of resonant frequency, as expected [23, 28].
Variation of the resonant frequency of the antenna was a promising result for further analysis as
it appears that this sensing mode should work. Thus additional simulations to determine the
resonant frequency under different conditions were conducted. Note that the graph of the return
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loss was given for different relative permittivity values of the blood vessel. The next chapter details
the correspondence between the relative permittivity of the blood itself.

2.9 Chapter Conclusion
In this chapter, the relevant literature was reviewed and the operational concepts behind
RF antenna glucose sensing was presented. The chapter describes the differences between
three possible sensing approaches: implantable active, implantable passive, and non-invasive
sensing.

The glucose-dependent properties of blood, and relevant previous works and

experimental findings are presented, along with appropriate human physiological characteristics
relevant for each type of sensing mode.

Sensor performance was predicted using

electromagnetic simulation tools to determine the anticipated resonance frequency of the antenna
in free space and for each type of sensing scenario using the presented human tissue models.
The optimization method of the antenna was explained and presented. Simulations for active
sensing were repeated over a range of relative permittivity values and the resonant frequency
found to be consistent with previous literature values. An analysis, including simulations, for the
passive sensing approach, were presented in parts. Unfortunately no conclusive results as to the
feasibility of this method were observed and this approach was abandoned. Finally, operational
simulations for non-invasive sensing were presented using the developed tissue model. These
results were so promising, an observed shift in resonance frequency as a function of blood
glucose, that further analysis is more than justified and will form the basis of the rest of this
dissertation.
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CHAPTER 3: NON-INVASIVE ANTENNA BLOOD GLUCOSE SENSOR

3.1 Chapter Overview
In the previous chapter, antennas for passive, active and non-invasive glucose sensing
were designed and simulated in HFSS within a human tissue model setup that considered the
permittivity, conductivity and thickness of skin, fat, blood and muscle. Of the three methods
studied, the last method – non-invasive glucose sensing – proved to be worthy of additional study.
The present chapter presents the results of experiments conducted to validate the promising
simulated results for the non-invasive approach. These experiments were conducted using a
semi-solid gel phantom that mimics the human tissue layers of skin, fat, blood, and muscle, RF
sensing was implemented, as discussed previously, using an RF antenna patch designed to
function in the ISM band at 5.8GHz. Simulated and experimental results are compared and
discussed. Variations such as skin thickness, blood vessel depth and misalignment of the sensor
with the blood vessel are presented and discussed.

3.2 Non-Invasive Antenna Experimental Measurements
3.2.1 Introduction to Human Tissue Phantoms
Conducting tests on a human tissue phantom instead of direct testing on human subjects
facilitates testing in a controlled environment as it eliminates variables such as movement,
respiration, temperature variation, among other variables. A variety of phantom recipes have
been proposed in the literature. Each recipe depends mainly on the testing application, while also
considering factors such as location of human tissue and sensor frequency. For instance, a
phantom to test the power absorption in biological tissue [51] which focuses on characteristics of
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the phantom for the given purpose, will be vastly different from that of a phantom for micro-imaging
of breast tissue [52], for the detection of traumatic brain injury [53], or to test the propagation of
radio frequency in the body. In the case of this research, the phantom constructed needs to mimic
the dielectric properties of the human skin, fat, blood and muscle in the upper arm area.

3.2.2 Human Tissue Phantoms Mimicking Electrical Properties
A recipe for a phantom that mimics the electrical properties has been reported [31]. The
preparation is made from de-ionized water, gelatin, NaCl, oil, and dishwasher detergent. The
gelatin serves as a collagen gelling agent to solidify the mixture. The dishwasher serves as a
surfactant agent. The de-ionized water is heated to the boiling point and then mixed with gelatin
until the mixture is completely dissolved. The mixture is left to cool to 35C, at which point the
NaCl and dishwasher detergent are slowly added to the mixture. When the temperature reaches
28C, the oil is slowly added to the mixture. The prepared solutions during the tests are left to
solidify for a period of 5 hours and measurements are taken within a period of 12 hours as no
preservatives are used in this recipe.
However, the recipe is given for a broadband application for a different frequency of 0.3
to 20GHz. The difference between the desired electrical properties at 5.8GHz for each layer and
those presented in [31] are too large to be used in the desired tests. Therefore, a modified recipe
was needed to mimic the permittivity and conductivity presented in [33, 38] for the skin, fat, blood
and muscle in the frequency range of interest (5.8GHz, ISM Band) and by the blood glucose
electrical property models presented in [27, 39]. The modification to the desired permittivity and
conductivity values was achieved by altering the oil and salt proportions of different mixtures. By
increasing the oil concentration, the relative permittivity is decreased while also affecting electrical
permittivity. By increasing the salt proportion, the electrical conductivity is increased while also
affecting the relative permittivity.

53

The dielectric properties were measured using ENA Network Analyzer model E5063A and
HP dielectric probe model 85070 using the coaxial probe method described in [54] as displayed
on Figure 54.

Figure 54: Coaxial probe method for measuring the permittivity of solids and semi-solids using
an HP dielectric probe model 85070 [55].

The human tissue phantom is composed of skin, fat, muscle and blood. The skin, blood
and muscle, for a frequency of 5.8GHz, are approximated as shown in Table 8. Note that in this
initial recipe, the blood has no added glucose. The fat phantom was made from pork tissue.
Measurements were taken from the sides and the center for each of the tissue samples, which
were distinguished by different food coloring (Figure 55).
Table 8: Human tissue phantom ingredients for upper arm for skin, fat and muscle
Human Tissue De-ionized water Gelatin
NaCl
Oil
Detergent
Skin
105g
12g
0.35g
31g
20g
*Blood (NG)
525g
60g
2.5g
40mg
100g
Muscle
315g
36g
0.751g
41g
60g
*Blood (NG) will refer to Blood (No glucose) during the rest of this dissertation.

Figure 55: HP Dielectric probe model 85070 measurement on each human tissue layer.
In order from left to right: a) fat phantom, b) blood phantom, c) muscle phantom and d) skin
phantom.
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The values obtained closely approximated the permittivity and conductivity values of the
skin, blood and muscle within the frequency range of 5.725 - 5.875 GHz. The measured versus
calculated relative permittivity and conductivity values are shown in Figure 56. The relative
permittivity and conductivity of the fat phantom is shown in Figure 57. Although the relative
permittivity and conductivity of the fat phantom were not matched to the optimal calculated fat
tissue electrical properties. However the variations were negligible, since the fat permittivity, which
measured approximately εr=6.5 as opposed to the optimal calculated value εr=5, was much lower
than the blood, skin and muscle values that range around εr=50. Therefore, the measured vs.
calculated blood, skin, and muscle tissue yielded a similar proportional value to the fat tissue.

Figure 56: Dielectric properties of human tissue phantoms for skin, muscle and blood.
Measured vs. calculated in the range of 4 to 7 GHz of εr (left) and σ (right).

Figure 57: Dielectric properties of the fat tissue phantom.
Measured vs. calculated values in the range of 5 to 7 GHz of εr (left) and σ (right).
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Additional phantom blood mixtures were prepared with the recipe previously described in
Table 9. For each 100g of de-ionized water in the mixture, 0.1 g, 0.3g, 0.5g, 1g, 2g, 4g of Sigma
D(+) glucose with a molecular mole concentration of 180.16g/mol was added for each phantom,
respectively. The dielectric properties of the glucose-containing blood phantoms were measured
using the HP dielectric probe 85070 shown in Figure 58. The relative permittivity measured was
graphed and compared with the calculated values [37] in Figure 59.

Figure 58: Photograph of HP dielectric probe model 85070 used to measure the dielectric
properties of the on blood glucose samples.

Figure 59: Permittivity, εr, of blood phantom samples with added D-glucose.
Measured results and calculated (black line) at frequencies between 4 to 7 GHz.
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The measured blood glucose permittivity for 5.74, 5.8 and 5.86GHz are plotted versus
glucose concentration and the data fitted with a polynomial trend.

For 5.8GHz, the fitted

polynomial equation of the measured blood phantom relative permittivity versus glucose is:
r (g5.8) = 0.0596 g5.82-0.7416 g5.8+52.642

(5)

where r is the measured relative permittivity of the blood phantom at 5.8GHz and (g5.8) is the
glucose concentration of the blood phantom in g/dL. Table 9 summarizes the blood phantom
glucose concentration vs. both measured and calculated relative permittivity.

Figure 60: Measured relative permittivity at 5.8GHz vs. glucose level.
Polynomial approximation fitted from 0 to 4000mg/dL (see equation (9)).
Table 9: D-Glucose concentrations in blood phantom and εr
D-glucose in blood Calculated Measured
D-glucose
phantom*
εr**
εr
[g]
[mmol[
[mmol/l]
[mg/dl]
52.642
52.635
0
0
0
0
52.611
0.1 0.55506 5.550622
100
52.568
52.466
0.3 1.66518 16.65186
300
52.425
52.250
0.5 2.77531 27.75311
500
52.286
51.847
1 5.55062 55.50621
1000
51.960
51.482
2 11.1012 111.01243 2000
51.397
50.616
4 22.2024 222.0248
4000
50.629
* For every 100ml of de-ionized water
** Calculated using Equation 1
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3.2.3 Experimental Measurements
3.2.3.1 Experimental Setup
The tissue phantom was assembled as follows. First the muscle layer was set as the
bottom (base) layer. Next the fat layer, containing a 2-mm wide groove to be replaced by a blood
phantom vessel layer, was added. Additional fat strips were then added to the top and bottom of
the blood vessel strip phantom, so that the phantom was leveled. Lastly the skin phantom was
added on top to complete the arm tissue phantom. The antenna was then placed over the skin
phantom in line with the blood vessel phantom. The antenna was fixed in a position with a
mechanical device to ensure the antenna’s position was 2mm above the skin phantom. Figure
61 shows the steps used in assembling each human tissue phantom while Figure 62 is a
photograph of the antenna within the holder being placed on human tissue phantom. To have
firmer phantoms for the assembly process, the phantoms were cooled to 5°C for one hour and
left at room temperature for another hour. This caused a slight bending on the sides of each
phantom. The corner regions were noted to not have the relative permittivity of interest, so the
antenna is placed at the center of the phantom where the values were as expected.

Figure 61: Steps for layering the human tissue with the blood vessel phantom.
The blood vessel phantom is buried in the fat layer to mimic the Cephalic vein of the upper arm.
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Figure 62: Photographic sequence showing the assembly of the human tissue phantom.
The 5.8GHz sense antenna is shown and mounted inside a 2 mm standoff to maintain the
optimum 2 mm spacing above the phantom.

3.2.3.2 Measured and Simulated Results
Measurements of the antenna patch were taken placing the antenna at 2 mm above the
human phantom and in direct line of sight of the blood vessel with the setup previously described
for blood glucose level 0, 100, 500, 1000 and 2000mg/dL. These were simulated over the 0 2000mg/dL glucose range using the equivalent relative permittivity calculated using Equation (5).
Figure 63 (top figure) plots both the simulated and measured return loss S11[dB] from 5.5 GHz to
6.1 GHz. The possible reasons for the variations observed between the simulated and measured
experiments is discussed in a later section. What can be highlighted from the results presented
here is that, through both methods, a shift of resonant frequency was detected due to variations
of relative permittivity in the blood vessel, which corresponds to a variation of glucose levels. For
glucose levels variations of 2000mg/dL, this shift of resonant frequency was found to be 13 MHz
from the measured data and 11MHz from the simulated data. To visualize this, a close-up graph
for the measured and simulated return loss are plotted in Figure 63 (bottom figures). The
measured close-up is plotted in the frequency range 5.75 to 5.95 GHz and the simulated closeup is plotted in the frequency range 5.75 to 5.85GHz.
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a)

b)

c)
Figure 63: Return loss of the antenna as a function of glucose concentration.
a) Measured and simulated plotted over range of 5.5 to 6.1GHz (top figure). b) Close-up of
measured. Note total variation of 13 MHz for glucose variation of 2000mg/dL. c) Close-up of
simulated return loss. Note total variation of 11 MHz for glucose variation of 2000mg/dL.

Figure 64 summarizes the measured and experimental results when the non-invasive
antenna was placed 2mm above the skin and centered over the blood vessel. It can be observed
that a glucose variation from 0 to 2000mg/dL resulted in a similar change in resonant frequency,
although there is a shift in the data as mentioned earlier. This shift can be due to variations of
thickness of the tissues layers used in the experimental setups, the slight variations of the
permittivity and conductivity thickness, as well as small variations during the fabrication process
of the antenna. Despite this shift, the resonant frequency variation based on glucose level
concentration has a similar trend.
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Figure 64: Measured and simulated fₒ vs. glucose concentration [mg/dL] and blood εr.
Note similar tendency values with an offset between experimental and simulated data.

Based on this data it seems feasible to use a single RF sensing antenna to extract glucose
information from blood in nearly real-time. What is needed now is the development of a sensor
platform that can perform these measurements in real-time with an automated output of the
assessed glucose value provided that setting the sense antenna properly can be achieved.
Chapter 4 presents the development of the sensor platform. First factors that lead to variations of
return loss must be properly understood, which are addressed in the next section.

3.3 Factors that Affect the Non-Invasive Antenna’s Return Loss
3.3.1 Physiological Factors
3.3.1.1 Skin Thickness and Resonant Frequency
Analysis of the effect of the skin thickness was simulated with and without the blood vessel
present. The skin thickness was varied from 1.5mm to 3.5mm, and the results plotted in Figure
65. Two distinct behaviors for simulations with blood vessel and without the blood vessel can be
observed. For locations where there is no blood vessel under direct line of sight of the antenna,
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for ranges lower than 2.2mm of skin thickness, decreasing the thickness of the skin decreases
the resonant frequency and for ranges above 2.2mm, increasing the thickness of the skin
decreases the resonant frequency. For areas where a blood vessel is in direct line of sight with
the antenna, this point of variation changes to around 3mm of skin thickness. For skin thickness
below 3mm, an increase of skin thickness results in an increase of resonant frequency, and for
skin thickness above 3mm, an increase of skin thickness results in a decrease of resonant
frequency. In a realistic average human tissue skin (2.44 - 2.48mm), a thicker skin would affect
the result in return loss by increasing the resonant frequency when above the a blood vessel,
while decreasing the resonant frequency if no blood vessel is in direct line of sight of the antenna.
This behavior is used during the calibration stage of the programming of the system, described in
chapter 4. Once calibrated, the variation of skin thickness person by person would not affected
the result, as the skin thickness remains unchanged for the same person over the testing period.
Regular calibration of the sensing system would keep the system prediction at the correct linear
change of glucose levels until the next recommended calibration.

Figure 65: Skin thickness variation effect on resonant frequency.
Simulated with human tissue model without blood glucose present.
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3.3.1.2 Deepness of the Blood Vessel
A second factor that varies from one individual to another is the depth of the blood vessel.
The targeted vessels are the ones located near the surface of the skin, but to test extreme values,
a depth variation of 2 to 3mm was assumed. To distinguish the effect due to blood vessel and its
depth, the model was evaluated with a glucose level of 300mg/dL. The results of this simulation
are shown in Figure 66 where it can be observed that a change in depth by 1 mm produces a shift
of resonant frequency of 50MHz.

Once again, this can be nulled out during the system

calibration as each patient’s vessel position is likely to be static.

Figure 66: Effect of blood vessel depth variation on resonant frequency.
A 50 MHz shift was observed for a depth change of 1 mm.

3.3.2 Misalignment of Antenna
3.3.2.1 Vertical Displacement
With the antenna centered over the blood vessel, the antenna’s vertical position above
the skin was varied from 0.5 to 3.5 mm in 0.5mm intervals. No significant variation of shift of
resonant frequency is presented when putting the antenna at different vertical elevated positions
from the skin. However, the amplitude peak at the resonance frequency experiences is different
at each position, where the deepest peak is found to be at 2mm above the skin. Although the
interest variation is frequency shift, it is of significant importance to maintain the vertical position
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stable as the technique used in the sensing system that will be described in chapter 4 involves
sampling the signal at different frequencies to detect the variations of reflected power level. For
this, the deepest peak is the one desirable, which is the 2mm distance from the skin. During the
experimental tests, as described in a previous section, the antenna is built on a holder that
ensures a 2mm distance from the skin. To implement this device in a realistic scenario, the 2mm
spacing can be controlled with a 2mm standoff placed between the skin and antenna.

Figure 67: Vertical variation effect on the return loss of the non-invasive antenna.
Return loss for blood vessel containing 700mg/dL of glucose (left). Return loss minimum
amplitude at resonant frequency vs. antenna distance from skin for different blood glucose
levels of 100, 300, 500 and 700mg/dL. Note optimum performance observed for 2mm height
above the skin.

3.3.2.2 Lateral Displacement
Until this point in the exploration of using a single sense antenna to non-invasively
estimate blood glucose level the antenna was aligned with the center of the blood vessel. The
effect of lateral displacement was determined by placing the antenna 2mm above the skin, using
a skin thickness of 2.48mm, and then displacing the antenna laterally from the blood vessel.
Figure 68 summarizes the effect on the observed resonant frequency due to lateral displacement
of the antenna. Notice that as the antenna is displaced further from the blood vessel, the resonant
frequency approaches the resonant frequency simulated with the human tissue model without a
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blood vessel which certainly makes sense as the antenna beam profile would not subtend the
vessel.

Figure 68: Simulated effect of antenna misaligned from blood vessel.
Note that the system response approaches that for no blood vessel, as expected, for large
displacements.

Clearly the effect of mechanical misalignment of the sense antenna, even after variations
in blood vessel depth and skin thickness have been calibrated out, is on par with the anticipated
change in resonant frequency due to glucose variations. Fortunately a ‘mechanical alignment’
strategy has been developed to address this issue and will be presented in Chapter 4 where it is
shown that an effective means for aligning the sense antenna with the blood vessel is both
possible and very practical.

3.4 Chapter Summary
The sense antenna was simulated and tested using a human tissue oil-in-water gel
phantom that mimics the dielectric properties (εr and σ) of skin, blood, fat and muscle. The
dielectric properties of each human tissue phantom were achieved by adding oil to decrease the
relative permittivity and adding salt to increase the electrical conductivity. D-glucose was added
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to the blood phantom in proportions of 100, 300, 500, 1000 and 2000mg/dL. Each phantom was
layered according to the human tissue model in which a blood vessel strip phantom was inserted
inside the fat phantom, with a bottom muscle phantom and a top skin phantom. The antenna was
fixed 2mm above the skin of the phantom using a constructed holder to ensure an even and
constant distance was achieved. The experimental result from the sense antenna to the above
mentioned variation of D-glucose level in the blood vessel was a 13MHz shift of resonant
frequency, with a similar trend to the simulated results which predicted a 11MHz shift of resonant
frequency.
Additional factors affect the resonant frequency of the non-invasive antenna and were
explored. The skin thickness varies in each human and a variation from 2mm to 2.48 mm can
produce a shift of resonant frequency up to 15MHz which is on the order of the glucose-dependent
shift. In addition blood vessel depth variations also affect the sensor output to a similar degree.
Fortunately this does not pose a problem, as the variations of D-glucose at the mentioned
difference are still observed and a person’s skin thickness and blood vessel location are constant
for each person. To use the non-invasive antenna as a sensor, the glucose dependent equation
should be calculated for each separate individual, thus these differences in tissue physiology can
be calibrated out for each user. The antenna being further or closer to the skin than the optimal
2mm distance causes a variation in the return loss amplitude while lateral displacement from the
blood vessel causes a lack of sensing functionality for a displacement of 1mm from the blood
vessel. Thus properly placing the sense antenna over the blood vessel is critical to being able to
measure blood glucose with this non-invasive sense antenna scheme. A practical strategy to
ensure that the antenna is in proper alignment has been explored and will be presented in Chapter
4. Thus the research presented in this chapter indicates that it should indeed be possible to
estimate blood glucose concentration in human blood using a non-invasive RF sense antenna
provided that proper care to antenna placement on the upper arm of the patient is made and
patient-to-patient tissue variations accounted for during system calibration.
66

CHAPTER 4: GLUCOSE SENSOR SYSTEM

4.1 Chapter Overview
In this chapter an electronic system platform for implementing the non-invasive glucose
sensing antenna as a complete sensor system is presented.

The sensor system platform

determines the blood glucose concentration of the blood vessel based on the measured shift of
the resonant frequency of non-invasive antenna patch sensor in the Industrial, Scientific and
Medical (ISM) Radio band (5.725GHz - 5.875GHz). The non-invasive blood glucose sensing
system components and connections, the measurements taken on each component and between
components/sub-systems, and a description of the algorithm used in the microcontroller to
determine the blood glucose level are all described. Additionally, a calibration alternative for
antenna misalignment correction by using lateral calibrating antennas is presented.
The system block diagram is shown below in Figure 69 with details provided in the next
section. In words an RF generator is used to drive the antenna, with a fraction of its output coupled
to both the antenna and receiver through a directional coupler. In this approach both the
transmitted (FWD) and reflected (REF) power are processed by demodulating logarithmic
amplifiers which convert the RF signals to corresponding voltages for downstream processing.
Both inputs are then fed into a microcontroller and the measured shift in resonant frequency, f O,
is converted to a real-time glucose concentration which is displayed on the sensor LCD display.

4.2 System Platform Hardware
The first sensor system component is the signal source to drive the antenna(s) in the ISM
band. This is an RF signal generator that generates frequencies from 5.725GHz to 5.875GHz in
intervals of 1MHz every 20µs. This signal enters a bi-directional coupler with a nominal coupling
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of 6dB and a forward directivity of 23dB. This is used to obtain continuous power reflection
measurements from the non-invasive antenna in reference of the forward power for each
frequency at its input.

The forward and reflected coupled signals then feed separate

demodulating logarithmic amplifiers to convert the RF input signal to a decibel-scaled output
voltage with a nominal logarithmic slope of -25mV/dB [55]. The microcontroller processes the
voltages from the demodulating logarithmic amplifiers to determine a blood glucose range based
on the sampled measurements at different glucose level.

Figure 69: Block diagram of system platform for non-invasive sensing.

4.2.1 Bi-Directional Coupler
The bi-directional coupler Amtery CP20008A, for frequencies from 0.5 to 8GHz, is a fourport network in which the traveling waves from the forward (through INPUT port) and the reverse
(through OUTPUT port) are coupled to two ports (FWD Coupled and REV Coupled ports). A
portion of the wave traveling from the INPUT port to the OUTPUT port is coupled to the FWD
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coupled port but not to the REV coupled port, and a portion of the OUTPUT port is coupled to the
REV coupled port but not the FWD coupled port. Figure 70 shows its electrical schematic [56]
and the connection to the non-invasive blood glucose sensing system platform.

Figure 70: Bi-directional coupler port connections to the circuitry.

Coupling is a measure of how much of the incident power is sampled and it is expressed
in decibels as 10𝑙𝑜𝑔

𝑃𝑖𝑛𝑐
,
𝑃𝑐𝑝

where Pinc is the power incident and Pcp is the power coupled. The

CP20008A bi-directional coupler has a nominal coupling factor of 6 dB for both forward and
reverse coupling. The directivity measures the extent to which the coupler distinguishes between
forward and reverse traveling waves. It is defined as the power output in the coupled port to the
𝑃𝑐𝑝

power flowing in the uncoupled port and is expressed in decibels as 10𝑙𝑜𝑔 𝑃 . Ideally, Pdir = 0
𝑑𝑖𝑟

(Directivity is infinite as no power should couple to the auxiliary port).
In its full range of 0.5 to 8 GHz, the CP20008A has a nominal directivity of 23dB in the
forward and 19dB in reverse direction [56]. The insertion loss, as well as the forward and reverse
coupling, were measured by inserting a signal generated by the RF Explorer signal generator
over the frequency range from 5.725GHz and 5.875GHz and is summarized in Figure 71. The
measured insertion loss was -1.73dB and -1.76dB, the forward coupling was -6.3dB and -6.18dB,
and the reverse coupling was -6.97dB and -6.85dB for frequencies 5.725GHz and 5.875GHz,
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respectively. At the sensor center frequency of 5.8GHz, the measured forward directivity was
33dB and reverse directivity was 24dB.

Figure 71: Measurements taken on coupler AMTERY model no. CP20008A.
a) Insertion loss, b) forward coupling, and c) reverse coupling.

The reverse port output was tested by inserting a signal in the INPUT port and driving the
non-invasive antenna from the OUPUT port. The forward coupled port was connected to a 50Ω
load and the reversed coupled port was connected to a network analyzer as shown in Figure 72.
Frequencies of 5.725, 5.8 and 5.875GHz were injected and the signal at the reverse port
measured under four conditions: 1) sense antenna in air, 2) antenna exposed to human tissue
phantom without blood vessel, 3) antenna exposed to human tissue phantom with blood vessel
containing 100mg/dL of glucose concentration, and 4) antenna exposed to human tissue phantom
with a blood vessel containing 2000mg/dL of glucose concentration. The data was recorded to
use for later microcontroller coding.

Figure 72: Measurement setup with bi-directional coupler and phantom.
The system was tested in the range of 5.725-5.875GHz for four mediums: 1) Air, 2) Human
tissue phantom without blood vessel – no glucose, 3) Human tissue phantom with blood vessel 100mg/dL glucose, and 4) Human tissue phantom with blood vessel - 2000mg/dL glucose.
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4.2.2 Demodulating Logarithmic Amplifier
The Analog Devices model no. AD8313 demodulating logarithmic amplifier consists of a
9-stage demodulating logarithmic amplifier, where each stage functions as a detector cell. The
logarithmic amplifier, also called a logarithmic converter, compresses a signal of wide range to its
decibel equivalence, thus converting the signal from one domain to another through a precise
nonlinear transformation. It employs progressive compression in which a “cascade of nonlinear
amplifier cells generates the logarithmic function from a series of contiguous segments” [55, 57].
The overall dc gain is high because the gain stages are dc-coupled. The device is fabricated using
a SiGe bipolar IC process, and is available in a 4mm x 4mm 16 lead package (type LFCSP). The
AD8318 is used in measurement mode to convert an RF input signal to a corresponding decibelscaled output voltage, as Vout decreases linearly in dB with the RF input signal. In this mode a
portion of VOUT is fed back to VSET [55]. The datasheet of the device specifies VOUT with the
following equation:
VOUT=X  VSLOPE/dB  20 x log 10 (Vin/Vintercept)

(6)

where X is the feedback factor in VSET= VOUT /X, VSLOPE/dB is nominally -25mV/dB, and VINTERCEPT
is 7dBV (20dBm, re: 50Ω or 2.239Vrms).
The minimum value for VOUT is VOUT = X  VOFFSET where VOFFSET is equal to 0.5V. The
maximum value for VOUT is VOUT =2.1  X, where VOUT cannot exceed 400mV below the positive
power supply voltage level. The non-invasive circuit prototype tested operated with a power
supply of 5V, and with X=1, therefore, the voltage variation range of the logarithmic amplifier was
0.5V to 2.1V.
The manufacturer’s datasheet specify a nominal VSLOPE/dB -25mV/dB, but this can vary from
device to device, so a board level calibration was performed. VOUT can be expressed as
VOUT = Slope  (PIN –Intercept)

(7)

where Slope = (VOUT1 - VOUT2) / (PIN1 - PIN2) and Intercept = PIN1- VOUT1/Slope.
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The device has a 10ns rise/fall time capability for input power switching between the noise
floor and 0dB [57]. The CLPF was left unconnected and the integration function is provided by a
1.5pF on-chip capacitor. The output of each AD8318 was measured by connecting the input to
the RF Explorer signal generator at 5.8GHz and at different power levels, in dBm, and measuring
the corresponding Vout using an oscilloscope, as shown in Figure 73.

Figure 73: Setup to characterize the demodulating logarithmic amplifier AD8318.
The RF Explorer was used as the source and a digital oscilloscope to capture the converted
voltage waveform.

Figure 74 displays the measured VOUT versus input signal power levels of -40, -30, -20,
-10 and -5dBm. Note that the device used had a measured slope of -22.9mV/dB, as well as a
parameter and variation error per measurement that needed to be considered during the coding
of the system.

Figure 74: Measured VOUT vs. PIN (dBm) at 5.8GHz using the setup of Fig. 83.
The observed slope is -22.9mV/dB which is within the specifications of the demodulating
logarithmic amplifier.

Measurement setup is displayed in Figure 75, which was done with antenna facing air, on
arm tissue without a blood vessel and with blood vessel at 500mg/dL. The results are displayed
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in Figure 76. Note that when 50 ohm is loaded on the REV port of the bi-directional coupler, the
FWD port is sufficiently constant for measurements in all three mediums to use as a reference
signal. The REV signal can be observed with a high peak at 5.85 GHz with a value 1.56V for a
phantom with no blood vessel (blue dashed line). The inversion of the signal from POUT to VOUT is
due to the discussed negative slope of -22.9mV/dB. When measuring antenna at phantom with
blood vessel with glucose level of 500mg/dL, a peak can be observed at 5.875GHz. In contrast,
when measuring antenna left measuring on empty air, the peak can be observed at 5.825GHz.
This measurement is repeated at a later instance with the complete system, being recorded the
highest peak at different frequencies for each of the mediums under test.

a)

b)

Figure 75: Measurement setup using the bi-directional coupler and logarithmic amplifier.
a) For forward coupling and b) for reverse coupling.

Figure 76: Preliminary test bi-directional coupler and the AD8318 for air, phantom without a
blood vessel and phantom with blood vessel at 500mg/dL.

73

4.2.3 PIC Microcontroller 18F4221
The microcontroller used, Model No. PC18F4321 from microchip in the prototype research
tests is an enhanced flash microcontroller with 10-bit Analog-to-Digital conversion (A/D) and
utilizes low-power “nanowatt technology” [58]. Additional features that could be incorporated are
communications via USART (Universal Synchronous and Asynchronous Receiver Transmitter) or
SPI (Serial Peripheral Interface) to other devices and/or a computer. Note that the microcontroller
was selected to test the prototype only and can be replaced by any microcontroller that fits the
basic requirements of analog input and external visualization of glucose level (by LCD (liquid
crystal display), cellphone, a computer, etc.). The dual in-line packaging (DIP) encapsulation was
used only during initial prototype testing on breadboards. Further tests are to be implemented on
a custom made printed circuit board (PCB), using the QFN (Quad Flat No-lead) encapsulation
packaging option. The microcontroller was programmed to calculate an estimate of the glucose
level based on the output voltages from the demodulating logarithmic amplifiers. The information
was then displayed on an LCD. Two analog ports were connected to the output signals of the
AD8318. Registers ADRESH and ADRESL, ADCON0, ADCON1 and ADCON2 were used to
configure the ports and activate the analog to digital conversion process. The program toggles
between two port conversion, where each analog port is processed and sampled. Each time one
of the two channels are sampled, a minimum acquisition time is fulfilled before starting the
conversion, where ½ Least Significant bit (LSb) error is used, having 1024 steps for the A/D
conversion [58].
In short, the AD conversion requires an acquisition time, a conversion time, and a
discharge time. The AD acquisition time depends on the amplifier settling time, the holding
capacitor charging time and the temperature coefficient. The charge holding capacitor (CHOLD) is
fully charged to the input channel voltage level before executing either conversion. This time is
affected directly by the source impedance (Rs) and the internal sampling switch (Rss). The CHOLD
is 25pF, Rs is 2.5KΩ, the conversion error is less than ½ LSb and VDD is 5V [58].
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The required times are therefore calculated as follows [58]:
TACQ = Amplifier Settling Time (TAMP) + Holding Capacitor Charging Time (TC) + Temperature Coefficient (TCOFF)

and are calculated as described by the device fabrication specifications [58] listed here:


TAMP



TC = -(CHOLD)(RIC+RSS+RS)ln(1/2047) = (25pF)(1KΩ+2KΩ+2.5KΩ)ln(0.0004883) = 1.05µs



TCOFF

= 0.2µs,

= 0 (working temperature of system below 25°C and does not require TC).

Once the acquisition time is fulfilled for the port (1.05µs as per above), the AD input
conversion begins and a bit GO/DONE is cleared once the conversion is complete. The discharge
initializes the value of the capacitor array. The time to complete a sampling conversion is
therefore 1.25 µs.

4.2.4 Glucose Meter Display
The non-invasive glucose estimate may then be displayed on a dedicated LCD screen, a
computer, or even a smart phone. During prototype testing, the results were displayed on a 2 x
16-character LCD. Note that this LCD was used in initial tests only, and could be miniaturized by
other LCD and will be discussed in the next subsection.

4.2.5 System Platform Miniaturization
The non-invasive blood glucose sensor system could continue to be researched as a
stand blood glucose measurement device in which a person introduces their arm into a
measurement device located at a fixed station, or could be developed as a wearable device where
the patient would carry the electronic device on their arm. In the case of a wearable device, the
microcontroller can be replaced by the PIC16F720, version QFN 4x4, which is ideal for
miniaturization purposes. This microcontroller is an extremely low power chip with a standby
current of only 40 nA @ 1.8 V and has the peripheral I/O pins as well as the basic features needed
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for this application including 128 bytes of non-volatile data storage, serial communication, an
internal oscillator of 16MHz, and built-in ADC channels.
The display could be made using LCD with the sharp LS010B7DH01, for placement over
the upper arm area. The dimensions are 1.64mm in thickness and 32.2 x 29.9 mm and the LCD
is controlled via a serial interface, thus minimizing the interconnection with the microcontroller.

4.3 Non-Invasive Sensing Algorithm
In Figure 77 the sensing antenna return loss curve is represented on the right figure and
analyzed at two frequencies in reference of the juxtaposed block diagram section on the left. If
the RF Generator drives a frequency fx, note that the return loss is at near 0dB. At this point the
antenna isn’t radiating and therefore most of the power is reflected back. Therefore, at frequency
fx, the output of the bi-directional coupler PREF will be at its maximum level, and the difference
between the PFWD and PREF will be at is minimum. On the other hand, at a frequency fy, the
antenna is at its deepest return loss point, meaning it is absorbing and radiating most of the power.
At this frequency, PREF will be at its minimum level, and the difference between the PFWD and PREF
will be maximum. All frequencies between fx and fy will result in intermedium values.

Figure 77: Antenna return loss power and bi-directional coupler output analysis.
Note the highlight at frequencies fx and fy in the S11 representation (right) and the implications
in the PFWD-PREF of the bi-directional coupler (left)
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In essence, the algorithm consists of sweeping the frequencies between 5.725 and 5.875
GHz and calculating the difference between PFWD and PREF. The results of each sweep are
recorded, and once the total differences at each frequency generated is computed, the result of
maximum difference in the total log indicates that at that moment, the antenna was at its resonant
frequency. To explain this, three scenarios will be discussed in which an antenna, when in
proximity to medium 1, resonates at frequency f1, when in proximity to medium 2 resonates at
frequency f2 and when in proximity to medium 3 resonates at frequency f 3, where f1<f2<f3, as
displayed in Figure 78.

Figure 78: Illustration of antenna resonating at different frequencies per medium.
Mediums 1, 2 and 3 make antenna resonate at frequencies f1, f2, and f3, respectfully.
If a frequency sweep f1, f2 and f3 is generated during times t1, t2 and t3, in the case of the
medium 1, the antenna is absorbing and radiating most of its power at f1, so the reflected power
will be at its lowest relative value during t1. In contrast, when the generated signal is f3, the
antenna is reflecting back most of the power. For medium 1, the antenna will have its lowest
power reflected (REV port) at frequency f1 during t1. This can best be visualized representatively
via the illustration in Figure 79. In contrast, if the same frequency sweep of f1, f2 and f3 is generated
with medium 2, which resonates at frequency f 2, the antenna is absorbing and radiating most of
its power during t2, so during this time REV will have the lowest power measurement, as illustrated
in Figure 79. If the frequency sweep is generated with medium 3, which resonates at f 3, the
reflected power will be the lowest during t3 while generating f3, as illustrated in Figure 81.
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Figure 79: Block illustration of signal generated at frequencies f1, f2, f3 and antenna facing
medium 1.

Figure 80: Block illustration of signal generated at frequencies f1, f2, f3 and antenna facing
medium 2.
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Figure 81: Block illustration of signal generated at frequencies f 1, f2, f3 and antenna facing
medium 3.

This algorithm may then be used to determine the resonant frequency of the antenna at
signals generated between 5.725 and 5.875GHz for intervals of 1MHz (150 frequency sweeps),
where the medium is the tissue phantom containing the blood vessel at a distinct glucose level.
The coupled forward and reverse RF signals are converted to their corresponding decibel-scaled
output voltage (VFWD and VREV) by the logarithmic amplifier AD8318. Note that the logarithmic
amplifier has a nominal negative slope of -25mV/dB, and was measured as shown in Figure 74.
Therefore, the resonant frequency will be shown by a maximum VOUT incoming from the REV port,
which is referred to as VREV. These voltages VREF and VFWD are input into analog ports AN0 and
AN1 of the microcontroller. Figure 82 displays a block diagram of the microcontroller registers,
where each AN0 and AN1 analog input is converted into a pair of registers ADRESH and
ADRESL, which are transferred as registers FWDH and FWDL for incoming data from AN0s and
REVH and REVL for incoming data from AN1.
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Figure 82: Non-invasive sensor system block diagram.
Microcontroller AD conversion to memory storage block diagram (region inside dotted
boundary).

The AD conversion is right justified, and variation only occurs in REVL and FWDL, but
REVH and REVH are used in initially during the calibration and sampling of data. The sample
data are stored in two memory sections for the current readings, where the addresses are
referenced depending on the frequency that is driving the antenna. The previous average
readings are stored in other two additional memory sections, where the addresses are also
reference depending on the frequency. Once a new reading takes place, the reading is averaged
with the stored previous readings, and the new value is stored in the memory section. Once the
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frequency sweep is completed, the system processes the average and the current reading.
During the next sweep, the new measurement is once again averaged to the previous reading.
This continuous reading eliminates possible errors due to movement, instrument errors or any
instantaneous error. In the average and current reading, the program looks for the maximum
stored value and the address at which it was stored, which corresponds to a frequency. Based
on this information, the system predicts the glucose levels based on a calibration measurement
stored in the microcontroller.
An example of a test measurement of the three mediums was conducted at a frequency
of 5.875GHz which three different mediums that resonate at 5.89, 5.87 and 5.8GHz, as shown in
Figure 95. Signals at the forward and reverse coupled ports, at the voltage output ports of the
logarithmic amplifier, and the expected register values of FWDL and REVL, were captured and
the numerical values are shown in Figure 83.

Figure 83: Sensor system test conducted at 5.875GHz for three different mediums.
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Note that with medium phantom 2, the resonant frequency was closest to the frequency
generated by the RF Signal generator as compared to the other phantoms. The output port REV
drops to -60.82dBm, while for phantom 1 and 2 they are within -52 and -56dBm. The output of
the Register REVL of the microcontroller will have the highest byte value at that instantaneous
sampling during the program.
Once the program inputs signal data at each frequency from 5.725GHz to 5.825GHz, the
program determines if it is valid data by analyzing if it is within a valid range stored in memory
from a pre-calibrated program. The pre-calibrated system uses a parameter DEVIATE to calibrate
the range of data deviation acceptance into the processing. The data will be continuously
computed averaging the new incoming data with the last data stored in memory for each given
frequency. These are stored in memory by indexing through assigned registers DIRAN0 and
DIRAN1 which contain a reference registers REFANO and REFAN1 that act as pointers, which
are averaged with previous stored data. Each average is stored in a second memory section for
VFWD cross-related to a third memory section for VREV. Finally, the program determines the
resonant frequencies by determining the highest ratio between VFWD and VREV and comparing this
to a pre-calibrated set of values stored in memory. The information is output to the LCD for user
observation. Figure 84 shows a picture of the system prototype during an air calibration routine.

Figure 84: Photograph of the evaluation prototype for non-invasive glucose sensing with parts
description.
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The program was trial tested in-vitro using five mediums: 1) the sensor antenna facing
air, 2) the sensor antenna 2mm above the pork tissue that mimicked surface of an arm with no
blood vessel detected and 3-5) above the pork tissue with a with silicone hose to circulate
mimicking blood with glucose levels 100mg/dL, 500mg/dL and 2000mg/dL (Figure 85). The
program was run and was able to positively identify the different mediums under test.

Figure 85: Photograph of the evaluation prototype for non-invasive glucose sensing under test
using pork tissue and mimicking liquid blood phantoms.

4.4 Registration of Antenna Placement over Blood Vessel
The measured results are highly dependent on the correct positioning of the antenna with
respect to the blood vessel, a point that was discussed theoretically in Chapter 3. For this, a
registration strategy is proposed in which two lateral antennas would serve as a reference to
position the sense antenna correctly. The registration strategy was simulated in ANSYS EM15.0
HFSSTM, where three antenna patches are placed in a diagonal position from each other as shown
in Figure 97 below.
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The system was simulated using the simplified human tissue model, where the muscle
and skin effect where disregarded, only analyzing the fat and blood vessel variation effect, to
obtain preliminary results and test the viability of the proposed registration model. The S11(1)
(reflected power of centered sense antenna), S11(2) (reflected power of antenna at side A), and
S11(3) (reflected power of antenna at side B) were computed for the blood vessel centered (dx=0)
and for it displaced by as much as 4 mm in intervals of 1 mm (i.e., dx=1, 2, 3 and 4) for each
blood glucose level. It can be observed in Figure 86 and Figure 87, which shows the antennas
in calibration model at dx=0, dx=1 and dx=2, that the difference between the resonant frequency
of calibrating antennas 2 and 3 is a minimum when the sensing antenna is centered over the
blood vessel.
Only when the antenna is parallel and centered over the blood vessel will the return loss
of the registration antennas approach the same resonant frequency with the same gain. Notice
in Figure 88 that even when the blood vessel is crossing the center of the sensing antenna,
because the blood vessel is not parallel to the patch antennas, the difference between the
calibrating antennas 2 and 3 is 13MHz (Antenna 2 resonates at 5.809GHz and antenna 3
resonates at 5.822GHz). In contrast, in previous case of parallel blood vessel and patch, both
antennas 2 and 3 resonated at 5.796GHz with the same minimum return loss peak. Therefore,
this method can serve for alignment technique.

Figure 86: Top view of calibration model parallel to blood vessel.
Two antennas are added at diagonal sides for sense antenna (center) registration.
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Figure 87: Return loss for sensing antenna and reference antennas..
a) Blood vessel centered with sensing antenna (dx=0), b) Blood vessel displaced 1mm
from sensing antenna (dx=1), and c) Blood vessel displaced 3mm from sensing antenna
(dx=3).

Figure 88: Top view of registration model at an angle with respect to the blood vessel.
In this case a 13 MHz shift between the antennas 2 and 3 occurs. Thus this strategy can be
used to both fix the proper angle as well as minimize any lateral offset, thus ensuring optimum
sensor performance.

4.5 Chapter Summary
A prototype system platform for a non-invasive blood glucose sensing system was
designed, built and tested. A frequency sweep between 5.725 to 5.875GHz was generated by
the RF Explorer Generator signal source and the signal coupled by a bi-directional coupler in
forward and reverse directions. A demodulating logarithmic amplifier converts the frequency into
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a decibel scaled voltage output. The microcontroller then converts each of the analog signals into
digital data, stores them in memory, averages the results, and then samples and compares the
data to calibration data in order to estimate the blood glucose level range. The total time of the
entire frequency sweep and the analog to digital conversion and processing is performed in
approximately 3µs with our prototype system and the estimated blood glucose displayed on a
dedicated LCD screen. A registration strategy was also presented to allow the user to optimize
the location of the antenna to minimize alignment errors thus increasing system sensitivity. This
was accomplished by placing two additional ‘registration’ antennas in diagonal position with
respect to the sense antenna. When the sense antenna is centered and parallel with the blood
vessel, the registration antennas resonate at nearly the same value thus allowing for a null-point
sensor patch alignment procedure to be implemented by the user.
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CHAPTER 5: CONCLUSIONS AND FUTURE WORK

5.1 Summary
The goal of this doctoral research was to explore the feasibility of an alternative blood
glucose level monitoring device via an RF sensor antenna operating in one of the approved
medical bands. This goal was explored by measuring the change in resonant frequency of an
antenna patch in proximity to a blood vessel versus different glucose levels in the ISM band (5.725
– 5.875 GHz). The underlying concept was based on an antenna’s resonant frequency being
dependent on a medium’s dielectric properties (relative permittivity and electrical conductivity)
that is within the beam of the antenna. Since numerous previous works have demonstrated that
blood relative permittivity decreases with an increase in blood glucose levels, this approach had
merit but had never been fully explored and proven. Therefore this doctoral research represents
a potential breakthrough in the quest to implement continuous glucose monitoring for patients
suffering from diabetes.
The current research analyzed the effect of blood relative permittivity variation on the
resonant frequency of an antenna in three different configurations: 1) Implanted as an active
sensor, 2) Implanted as a passive sensor to be interrogated by external antenna(s), and 3) as a
non-invasive sensor by placing the antenna above the upper arm skin. The antennas were
designed using a 635µm thick Rogers 6010 substrate (𝜀r=10.2, tan δ = 0.0023). The research
used the electromagnetic simulation tool Ansoft EM15.0 HFSSTM to model the antenna using
realistic published human tissue physiological and electrical properties of skin, fat, blood and
muscle. For the implantable active and passive sensor versions, the model was designed for the
abdominal area of the body, whereby the antenna was to be implanted in a fatty tissue layer in
close proximity to blood vasculature. For the non-invasive sensor, the antenna was designed for
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the upper arm area to be above the skin and in line with the cephalic vein. Perfectly matched
layer boundaries were set for each boundary layer of the human tissue model to eliminate
electromagnetic reflection during all simulations.
The antenna patch was initially designed to operate at 5.8GHz in free space and later
optimized to operate inside the body, for the active and passive sensor configurations, and at the
external surface of the body for the non-invasive configuration. Antenna optimization was
accomplished by varying the size of the patch antenna and the distance from the patch center to
the feed. The resulting active antenna dimensions were a rectangular patch of 4.1x7.1mm over
a substrate of 10mil thickness and 2.4x1.9cm in dimension, and with a feed displaced 1.4mm in
the Y direction. The blood permittivity was varied from 62.0 to 63.6 in steps of 0.2 using a discrete
sweep, resulting in a total resonance frequency variation for this range from 5.76 to 5.78 GHz,
respectively (i.e., 20 MHz). In addition these results indicate that at greater glucose levels, the
antenna will experience a decrease resonant frequency. The results indicated the potential of the
antenna as an implantable sensor in this frequency band. To realize a blood glucose system, a
circuit platform with batteries (or other energy source) would also need to be designed to be
implanted in the body to make this functional.

Therefore, further research and design of

miniaturized circuitry for this approach would be required to bring this continuous glucose
measuring system to the marketplace.
For the passive sensing approach, the implanted antenna was intended to be a standalone passive device inside the body, with no additional implanted circuitry or energy source such
as batteries. The implanted antenna needed to perform two tasks: 1) to sense blood glucose
levels inside the body by facing a major blood vessel, and 2) to communicate with two external
antennas outside the body. The design of the active sensor fulfilled the first mentioned task. For
the second task, a transmitting antenna needed to send the signal to the passive antenna, where
it be reflected back to the receiving antenna with a shift in frequency corresponding to glucose
level. Simulations of this concept were run by placing the external antennas in proximity of the
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human tissue model separated by 1mm, 10mm and 20mm with no implant, and by adding
implanted parts of the passive antenna in the fatty area at 2mm and at 7mm from blood vessel.
When the antennas were separated by 1mm, an implant affected the S21 of the external antennas
by less than 1dB at around the -12dB level. Having the antennas separated by 20 mm, although
the implant affected the signal by about 10dB, the S21 signal was around the -40dB level. In
conclusion, although there was less effect by having the antennas separated by 1mm, this
separation distance allowed for a stronger signal. The blood permittivity was varied from 62.0 to
63.6. Unfortunately no variation was observed with the human tissue model based on blood
variation in permittivity. The variations obtained were due to the location of the implant and not
to the variation of blood glucose level. The test was repeated having a blood vessel in air
boundaries, in which the S21 signal variation was based on blood glucose variation but less than
1MHz.

No conclusive positive results were obtained to pursue further the passive implant

approach. Furthermore, this approach also requires an implant and requires external circuitry,
which makes this the least practical option for commercial use.
The third and final method that was explored was the non-invasive approach, in which an
antenna patch was placed externally over the upper arm in direct line of sight of a blood vessel.
The blood relative permittivity was again varied, with an increase in resonance frequency as the
blood relative permittivity increased observed. Variation of εr from 51.397 to 52.642 in the blood
vessel caused a resonant frequency variation of approximately 10.5MHz on the antenna, which
is the principal reason why this last sensing approach underwent further research to compare with
simulated results.
The experimental tests of the non-invasive antenna approach were conducted using an
oil-in-gel phantom that mimicked the dielectric properties (εr and σ) of skin, blood, fat and muscle,
and an arm tissue model was constructed using each layer. The recipe was a modified version
from published works by altering the proportions of oil and salt in the phantom to obtain the desired
relative permittivity and electrical conductivity at frequencies from 5.725 to 5.875GHz. D-glucose
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was added to the blood phantom in proportions of 100, 300, 500, 1000 and 2000mg/dL which
caused a measured variation of εr=52.635 to εr=51.482, which were approximated to εr from 52.64
to 51.40 for numerical simulation purposes. Once the desired electrical properties for each tissue
layer was achieved, the human tissue model was constructed by inserting the blood vessel as a
strip phantom inside the fat phantom, with a bottom muscle phantom and a top skin phantom.
The antenna was then located 2mm above the skin using a constructed holder to ensure even
and fixed distance between the antenna and the arm.

The experimental results with the

mentioned variation of D-glucose level in the blood vessel resulted in a 13MHz shift of resonant
frequency, with a similar fit trend as the simulated results. This, in a general sense, was validation
of the numerical model executed in HFSS™ and justification for further development of the noninvasive sensor approach.
Further tests were carried out to determine the effect of variations that exist between
different people, such as skin thickness and blood vessel depth, and variations due to any
misalignment of the sense antenna with respect to the blood vessel. It was found that skin
thickness variation from the 2mm to 2.48 mm can produce a shift of resonant frequency up to
15MHz. Depth variation was evaluated for extreme differences of 1mm of the blood vessel
location, which can cause up to a 50MHz variation. Nevertheless, we do not believe that the skin
and vessel depth variation from different individuals poses a problem, as these variables are
stable for each person, and the variation due to D-glucose at the mentioned difference were still
observed.

Naturally proper sensor calibration would need to be performed by the medical

professional when fitting the sensor system to the patient. To use the non-invasive antenna as a
glucose sensor, the glucose dependent equation should be calculated for each separate
individual and calibrated for each person. Misalignment of antenna was also determined by
displacing the antenna further or closer to the skin, and by displacing it laterally away from the
blood vessel. Although vertical misalignment does not produce significant variation in frequency,
it does produce variations in the peak minimum of the resonant frequency, and must be stabilized
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due to the technique used in the system to determine the resonant frequency. The distance from
the skin can be stabilized by having the antenna in a holder that ensures a 2mm distance from
the skin. The lateral displacement had a significant variation if no correctly aligned with the blood
vessel. This can be corrected by a registration mechanism in which two additional antennas
placed above and below the sense antenna, and in a diagonal direction, serve to alert the user of
any a misplacement of the antenna so the user or caregiver could correctly re-align the sensing
antenna.
Finally, an electronic system platform to implement the non-invasive sensing antenna was
designed in which a circuit system platform determined the blood glucose concentration in a blood
vessel based on the shift of the resonant frequency of a non-invasive antenna patch sensor in the
Industrial, Scientific and Medical (ISM) Radio band (5.725GHz - 5.875GHz). An RF generator
was used to drive the antenna, with a fraction of its output coupled to both the antenna and
receiver through a directional coupler. The transmitted and received RF power were converted
to a decibel scaled output voltage and fed into a microcontroller. The microcontroller processed
the data to display the estimated glucose concentration on a dedicated LCD screen.

5.2 Recommendations and Future Work
The active sensing antenna has the potentiality to undergo further research. In this
configuration, the antenna was evaluated as a sensing device only, but did not include any
research on the internal circuitry and the communication with outside the body. To be implanted
inside the body, the antenna would need to be constructed using a biocompatible material such
as Silicon Carbide, such as evaluated by research in references [23] and [28]. Furthermore, this
antenna would need an energy source and circuitry. The energy source could derive from energy
harvesting or could be an implanted battery. When a glucose level is above or below a specified
level, the antenna should be able to communicate with an external device to alert the patient, or

91

be able to have control mechanisms to correct the problem such controlling the output of an insulin
pump such as is displayed in Figure 86.

Figure 89: Implantable blood glucose sensing system to control insulin pump.

A second further work consists in additional research for the non-invasive antenna. In this
path, an analysis needs to be conducted on different patients to obtain real time data on different
areas of the arm, categorized by age, sex, weight, and other factors that distinguish each patient
under test. The data should be crossed referenced with the glucose level and health conditions
of the patient. This can be added in the calibration program. All simulations done in this research
could be repeated using the basilic vein instead of the cephalic vein, and other major veins in the
body and compare the results with the ones presented on this research. Additional tests such as
temperature variation of patient should also be evaluated.

Further work include the

miniaturization of the prototype for a wearable device application, or the construction as a standalone device where an arm can be inserted in a tubular device with an antenna or several
antennas within, as displayed in Figure 90. As the patient inserts the arm, the tubular device
could rotate, or could be stationary and have multiple antennas inside the tube, where sampling
is activated one at a time. The sampling of different sections of the arm can add accuracy.
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Figure 90: Stand-alone glucose monitoring system with antennas in tubular device.
The tubular device could rotate or have added antennas for additional measurement points for
added accuracy due to multiple arm reference points.
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eliminating sections of the original arm illustration that were not needed for this research purpose)
to display intended message of this research. Thus this illustration differs substantially from the
original illustration.
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